COMBINED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMOR - Patent application

The combination of an anti-PD-L1 antibody and anlotinib provides a more effective treatment for biliary tract tumors, liver cancer, and lung cancer by enhancing tumor suppression and eradication with reduced side effects and improved survival rates.

JP7582952B2Active Publication Date: 2024-11-13CHIA TAI TIANQING PHARMA GRP CO LTD +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021543515
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-01-25
Filing Date
2020-01-23
Publication Date
2024-11-13
Estimated Expiration
2040-01-23

AI Technical Summary

Technical Problem

Current treatments for proliferative diseases such as cancer lack effective drug combinations that can enhance tumor suppression and eradication, while existing therapies often require higher dosages and cause significant side effects.

Method used

A combination pharmaceutical composition comprising an anti-PD-L1 antibody and anlotinib, formulated in various doses and ratios, is administered to treat biliary tract tumors, liver cancer, triple negative breast cancer, and lung cancer, allowing for simultaneous or sequential administration to optimize treatment efficacy.

Benefits of technology

The combination therapy demonstrates superior tumor suppression and eradication capabilities with lower dosages, improved tolerability, and longer survival rates compared to single-drug administration, showcasing enhanced disease control and reduced side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007582952000001
    Figure 0007582952000001
  • Figure 0007582952000002
    Figure 0007582952000002
  • Figure 0007582952000003
    Figure 0007582952000003
Patent Text Reader

Abstract

This application relates to a pharmaceutical combination composition for treating biliary tract tumors, liver cancer, triple-negative breast cancer, or lung cancer, which comprises an anti-PD-L1 antibody and anlotinib and has excellent anti-biliary tract tumor, liver cancer, triple-negative breast cancer, or lung cancer activity.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present application is in the field of biological therapy and concerns a combination pharmaceutical composition for tumor treatment. [Background technology]

[0002] Tyrosine kinases are a group of enzymes that catalyze the phosphorylation of tyrosine residues in proteins, and play an important role in intracellular signal transduction. They are involved in the control, signal transduction, and development of normal cells, and are also closely related to the proliferation, differentiation, migration, and apoptosis of tumor cells. Many receptor tyrosine kinases are involved in tumorigenesis, and are classified into epidermal growth factor receptors (EGFRs), platelet-derived growth factor receptors (PDGFRs), vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), etc., depending on the structure of their extracellular domains.

[0003] PD-L1 (Programmed death-ligand 1), also known as CD247 or B7-H1, is a ligand of programmed cell death protein 1 (PD-1). PD-L1 is highly expressed on the surface of various tumor cells, and the malignancy and poor prognosis of tumors are closely related to the expression level of PD-L1. In the tumor microenvironment, PD-L1 on the surface of cancer cells binds to PD-1 or CD80 on the surface of T cells, inhibiting the activation and proliferation of T cells, inducing effector T cells to an exhausted or unresponsive state, promoting the apoptosis of T cells, and promoting the differentiation of helper T cells into regulatory T cells, thereby blocking the killing effect of T cells on tumor cells. Anti-PD-L1 antibodies block the interaction of PD-L1 with PD-1 and CD80, thereby preventing the initiation and transmission of related negative regulatory signals, avoiding the inhibition of the activity of effector T cells in the tumor microenvironment, and allowing T cells to exert their function of killing or inhibiting tumor cells. Anti-PD-L1 antibodies can act directly on tumor tissue, making them highly specific and safe.

[0004] WO2016022630 discloses an anti-PD-L1 antibody that has high affinity for PD-L1, significantly inhibits the interaction between PD-L1 on the cell surface and PD-1, and significantly promotes the secretion of IL-2 and INF-γ by T cells.

[0005] Although many options are available for treating patients with proliferative diseases (eg, cancer), there is a clinical need for more effective agents, especially multi-drug combinations. Summary of the Invention

[0006] One aspect of the present application provides a combination pharmaceutical composition comprising an anti-PD-L1 antibody and anlotinib.

[0007] Further, anlotinib may be in the form of a free base or in the form of a pharma- ceutically acceptable salt thereof. For example, a pharma- ceutically acceptable salt of anlotinib may be the hydrochloride or dihydrochloride salt.

[0008] In addition, the anti-PD-L1 antibody may comprise a heavy chain CDR1 region that has at least 80% homology to the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:4, a heavy chain CDR2 region that has at least 80% homology to the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:5, a heavy chain CDR3 region that has at least 80% homology to the amino acid sequence set forth in SEQ ID NO:3 or SEQ ID NO:6, a light chain CDR1 region that has at least 80% homology to the amino acid sequence set forth in SEQ ID NO:7 or SEQ ID NO:10, a light chain CDR2 region that has at least 80% homology to the amino acid sequence set forth in SEQ ID NO:8 or SEQ ID NO:11, and a light chain CDR3 region that has at least 80% homology to the amino acid sequence set forth in SEQ ID NO:9 or SEQ ID NO:12. and a light chain CDR3 region having an amino acid sequence of at least 80% homology to the amino acid sequence of SEQ ID NO:1. Furthermore, the anti-PD-L1 antibody comprises a heavy chain CDR1 region selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:4, a heavy chain CDR2 region selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:5, a heavy chain CDR3 region selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:6, a light chain CDR1 region selected from the group consisting of SEQ ID NO:7 and SEQ ID NO:10, a light chain CDR2 region selected from the group consisting of SEQ ID NO:8 and SEQ ID NO:11, and a light chain CDR3 region selected from the group consisting of SEQ ID NO:9 and SEQ ID NO:12. Furthermore, the anti-PD-L1 antibody comprises a heavy chain CDR1 region having the amino acid sequence set forth in SEQ ID NO:1, a heavy chain CDR2 region having the amino acid sequence set forth in SEQ ID NO:2, a heavy chain CDR3 region having the amino acid sequence set forth in SEQ ID NO:3, a light chain CDR1 region having the amino acid sequence set forth in SEQ ID NO:7, a light chain CDR2 region having the amino acid sequence set forth in SEQ ID NO:8, and a light chain CDR3 region having the amino acid sequence set forth in SEQ ID NO:9. Furthermore, the anti-PD-L1 antibody comprises a heavy chain variable region having at least 80% identity to the amino acid sequence set forth in the following amino acid sequences: SEQ ID NO: 13 or SEQ ID NO: 14, and a light chain variable region having at least 80% identity to the amino acid sequence set forth in SEQ ID NO: 15 or SEQ ID NO: 16. Furthermore, the anti-PD-L1 antibody comprises a heavy chain variable region selected from the group consisting of heavy chain variable regions of hu13C5-hIgG1, hu13C5-hIgG4, hu5G11-hIgG1, and hu5G11-hIgG4 humanized antibodies, and a light chain variable region selected from the group consisting of light chain variable regions of hu13C5-hIgG1, hu13C5-hIgG4, hu5G11-hIgG1, and hu5G11-hIgG4 humanized antibodies.

[0009] Additionally, the combination pharmaceutical composition of the present disclosure may be packaged in a kit, the kit further comprising instructions for the combination of the anti-PD-L1 antibody with anlotinib in the treatment of biliary tumors, liver cancer, triple-negative breast cancer, and / or lung cancer.

[0010] The present application further provides a combination pharmaceutical composition comprising a pharmaceutical composition comprising 600-2400 mg of an anti-PD-L1 antibody and a pharmaceutical composition comprising anlotinib in a single dose of 6 mg, 8 mg, 10 mg, and / or 12 mg, where the pharmaceutical composition comprising the anti-PD-L1 antibody is in a single dose or in multiple doses.

[0011] Furthermore, the present application provides a combination pharmaceutical composition comprising a pharmaceutical composition comprising 600-2400 mg of an anti-PD-L1 antibody in multiple doses, and a pharmaceutical composition comprising anlotinib in a single dose of 6 mg, 8 mg, 10 mg, and / or 12 mg.

[0012] Furthermore, the present application provides a combination pharmaceutical composition comprising a pharmaceutical composition comprising 600-2400 mg of an anti-PD-L1 antibody and 84-168 mg of anlotinib, the combination pharmaceutical composition being a formulation suitable for administration within a single treatment cycle (e.g., one treatment cycle is 21 days).

[0013] Furthermore, the present application provides a combination pharmaceutical composition comprising an anti-PD-L1 antibody and anlotinib in a weight ratio of (0.35-29):1, preferably (3.5-29):1, more preferably (3.5-14.5):1, and most preferably (7-14.5):1, where the anti-PD-L1 antibody and anlotinib may be packaged separately or together. In addition, anlotinib may be packaged in multiple equal parts (e.g., 2 equal parts, 7 equal parts, 14 equal parts, 28 equal parts or more), and the anti-PD-L1 antibody may be packaged whole or in multiple equal parts (e.g., 2 equal parts, 4 equal parts or more).

[0014] The present application also provides a combination pharmaceutical composition for treating biliary tumors, liver cancer, triple-negative breast cancer, and / or lung cancer, comprising an anti-PD-L1 antibody and anlotinib.The present application also provides a method for treating biliary tumors, liver cancer, triple-negative breast cancer, and / or lung cancer, comprising administering to a subject an effective amount of the combination pharmaceutical composition of the present disclosure. The present application also provides a use of the combined pharmaceutical composition in the manufacture of a medicament for treating biliary tumors, liver cancer, triple-negative breast cancer, and / or lung cancer. Alternatively, the present application provides a use of an anti-PD-L1 antibody and anlotinib in the manufacture of a medicament for treating biliary tumors, liver cancer, triple-negative breast cancer, and / or lung cancer.

[0015] Furthermore, the anti-PD-L1 antibody and anlotinib are each in the form of a pharmaceutical composition and may be administered simultaneously, sequentially, or at intervals. Furthermore, the anti-PD-L1 antibody is administered once a week, every two weeks, every three weeks, or every four weeks, and preferably, the anti-PD-L1 antibody is administered at a dose of 600-2400 mg. Furthermore, anlotinib is administered at a dose of 6 mg, 8 mg, 10 mg, or 12 mg once daily, with a treatment regimen of two weeks on and one week off.

[0016] The present application also provides a kit for treating biliary tract tumors, liver cancer, triple-negative breast cancer, and / or lung cancer, the kit comprising a pharmaceutical composition of an anti-PD-L1 antibody, a pharmaceutical composition of anlotinib, and instructions for use of the anti-PD-L1 antibody in combination with anlotinib in the treatment of biliary tract tumors, liver cancer, triple-negative breast cancer, and / or lung cancer.

[0017] Furthermore, the kit is suitable for administration within one treatment period (e.g., one treatment period is 21 days) and comprises a pharmaceutical composition comprising 600 to 2400 mg of an anti-PD-L1 antibody and a pharmaceutical composition comprising 84 to 168 mg of anlotinib.

[0018] In a first aspect, the present application provides a combination pharmaceutical composition for treating biliary tract tumors, comprising an anti-PD-L1 antibody and anlotinib.

[0019] As a further aspect of the present application, there is provided a use of the combination pharmaceutical composition for manufacturing a medicament for treating a biliary tumor. The present application further provides a method for treating a biliary tumor, comprising administering to a subject an effective amount of the combination pharmaceutical composition of the present disclosure. The present application further provides a use of the combination pharmaceutical composition for treating a biliary tumor. The combination pharmaceutical composition comprises an anti-PD-L1 antibody and anlotinib.

[0020] As a further aspect of the present application, there is provided a use of a combination of an anti-PD-L1 antibody and anlotinib for the manufacture of a medicament for treating a biliary tract tumor. The present application further provides a method for treating a biliary tract tumor, comprising administering to a subject an effective amount of an anti-PD-L1 antibody and anlotinib. The present application further provides a use of a combination of an anti-PD-L1 antibody and anlotinib for treating a biliary tract tumor. The present application further provides a combination of an anti-PD-L1 antibody and anlotinib for treating a biliary tract tumor.

[0021] In a second aspect, the present application provides a combination pharmaceutical composition for treating liver cancer, comprising an anti-PD-L1 antibody and anlotinib.

[0022] As a further aspect of the present application, there is provided a use of a combination pharmaceutical composition in the manufacture of a medicament for treating liver cancer. The present application further provides a method for treating liver cancer, comprising administering to a subject an effective amount of the combination pharmaceutical composition of the present disclosure. The present application further provides a use of a combination pharmaceutical composition in treating liver cancer. The combination pharmaceutical composition comprises an anti-PD-L1 antibody and anlotinib.

[0023] In a further aspect of the present application, there is provided a use of a combination of an anti-PD-L1 antibody and anlotinib for the manufacture of a medicament for treating liver cancer. The present application further provides a method for treating liver cancer, comprising administering to a subject effective amounts of an anti-PD-L1 antibody and anlotinib. The present application further provides the use of a combination of an anti-PD-L1 antibody and anlotinib in treating liver cancer.The present application further provides a combination of an anti-PD-L1 antibody and anlotinib for treating liver cancer.

[0024] In a third aspect, the present application provides a combination pharmaceutical composition for treating triple-negative breast cancer, comprising an anti-PD-L1 antibody and anlotinib.

[0025] As a further aspect of the present application, there is provided a use of a combination pharmaceutical composition in the manufacture of a medicament for treating triple-negative breast cancer. The present application further provides a method for treating triple-negative breast cancer, comprising administering to a subject an effective amount of a combination pharmaceutical composition of the present disclosure. The present application further provides a use of a combination pharmaceutical composition in the treatment of triple-negative breast cancer. The combination pharmaceutical composition comprises an anti-PD-L1 antibody and anlotinib.

[0026] As a further aspect of the present application, there is provided a use of a combination of an anti-PD-L1 antibody and anlotinib in the manufacture of a medicament for treating triple-negative breast cancer. The present application further provides a method of treating triple-negative breast cancer, comprising administering to a subject an effective amount of an anti-PD-L1 antibody and anlotinib. The present application further provides a use of a combination of an anti-PD-L1 antibody and anlotinib in treating triple-negative breast cancer. The present application further provides a combination of an anti-PD-L1 antibody and anlotinib for treating triple-negative breast cancer.

[0027] In a fourth aspect of the present application, there is provided a combination pharmaceutical composition for treating lung cancer, comprising an anti-PD-L1 antibody and anlotinib.

[0028] As a further aspect of the present application, there is provided a use of a combination pharmaceutical composition in the manufacture of a medicament for treating lung cancer. The present application further provides a method for treating lung cancer, comprising administering to a subject an effective amount of a combination pharmaceutical composition of the present disclosure. The present application further provides a use of a combination pharmaceutical composition in the treatment of lung cancer. The combination pharmaceutical composition comprises an anti-PD-L1 antibody and anlotinib.

[0029] As a further aspect of the present application, there is provided a use of a combination of an anti-PD-L1 antibody and anlotinib in the manufacture of a medicament for treating lung cancer. The present application further provides a method of treating lung cancer, comprising administering to a subject effective amounts of an anti-PD-L1 antibody and anlotinib. The present application further provides a use of a combination of an anti-PD-L1 antibody and anlotinib in treating lung cancer. The present application further provides a use of a combination of an anti-PD-L1 antibody and anlotinib to treat lung cancer. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] The present application provides a combination pharmaceutical composition comprising an anti-PD-L1 antibody and anlotinib. In some embodiments of the present application, the combination pharmaceutical composition is used to treat a tumor or cancer. In some embodiments of the present application, the tumor or cancer is selected from the group consisting of biliary tumors, liver cancer, triple-negative breast cancer, and lung cancer.

[0031] COMBINED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF BILIARY TUMORS - Patent application In one embodiment of the present application, there is provided a combination pharmaceutical composition for treating biliary tract tumors, comprising an anti-PD-L1 antibody and anlotinib.

[0032] In some embodiments of the present application, the combination pharmaceutical composition comprises a pharmaceutical composition of an anti-PD-L1 antibody and a pharmaceutical composition of anlotinib.

[0033] In some embodiments of the present application, the combination pharmaceutical composition is packaged in a kit, and the kit further comprises instructions for the combination of the anti-PD-L1 antibody with anlotinib in the treatment of biliary tract tumors.

[0034] In some embodiments, there is provided a combination pharmaceutical composition for treating biliary tract tumors, comprising a pharmaceutical composition comprising 600-2400 mg of an anti-PD-L1 antibody and a pharmaceutical composition comprising anlotinib in a single dose of 6 mg, 8 mg, 10 mg, and / or 12 mg, where the pharmaceutical composition comprising the anti-PD-L1 antibody is in a single dose or in multiple doses.

[0035] In some embodiments, there is provided a combination pharmaceutical composition for treating biliary tract tumors, comprising a pharmaceutical composition comprising 600-2400 mg of an anti-PD-L1 antibody in multiple doses, and a pharmaceutical composition comprising anlotinib in a single dose of 6 mg, 8 mg, 10 mg, and / or 12 mg.

[0036] In some embodiments, there is provided a combination pharmaceutical composition for treating biliary tumors, comprising an anti-PD-L1 antibody and anlotinib in a weight ratio of (0.35-29):1, preferably (3.5-29):, more preferably (3.5-14.5):1, and most preferably (7-14.5):1, where the anti-PD-L1 antibody and anlotinib may be packaged separately or together, and anlotinib may be packaged in multiple equal portions (e.g., 2 equal portions, 7 equal portions, 14 equal portions, 28 equal portions or more).

[0037] In some embodiments, there is provided a combination pharmaceutical composition for treating biliary tract tumors, comprising a pharmaceutical composition of an anti-PD-L1 antibody and a pharmaceutical composition of anlotinib, wherein the pharmaceutical composition of the anti-PD-L1 antibody is formulated to be suitable for administering to a patient a single dose or multiple doses of 600-2400 mg of the anti-PD-L1 antibody upon first administration, and the pharmaceutical composition of anlotinib is formulated to be suitable for administering to a patient a single dose of 6 mg, 8 mg, 10 mg, and / or 12 mg of anlotinib daily for 14 days.

[0038] In some embodiments, there is provided a combination pharmaceutical composition for treating biliary tract tumors, comprising a pharmaceutical composition of an anti-PD-L1 antibody comprising 10-60 mg / mL of anti-PD-L1 antibody, and a pharmaceutical composition comprising anlotinib in a single dose of 6 mg, 8 mg, 10 mg, and / or 12 mg.

[0039] In some embodiments, there is provided a combination pharmaceutical composition for treating biliary tract tumors, comprising a pharmaceutical composition of an anti-PD-L1 antibody comprising 10 mg / mL anti-PD-L1 antibody, and a pharmaceutical composition comprising anlotinib in a single dose of 8 mg and / or 10 mg.

[0040] In some embodiments, there is provided a combination pharmaceutical composition for treating biliary tract tumors, comprising a pharmaceutical composition comprising 1200 mg of an anti-PD-L1 antibody in multiple doses, and a pharmaceutical composition comprising anlotinib in a single dose of 8 mg and / or 10 mg.

[0041] As a further aspect of the present application, there is provided a use of the combination pharmaceutical composition in the manufacture of a medicament for treating a biliary tract tumor. The present application further provides a method for treating a biliary tract tumor, comprising administering to a subject an effective amount of the combination pharmaceutical composition of the present disclosure. The present application further provides a use of the combination pharmaceutical composition in treating a biliary tract tumor. In some embodiments, the combination pharmaceutical composition comprises an anti-PD-L1 humanized monoclonal antibody and anlotinib.

[0042] In a further aspect of the present application, there is provided a use of a composition of an anti-PD-L1 antibody and anlotinib in the manufacture of a medicament for treating a biliary tract tumor. The present application further provides a method for treating a biliary tract tumor, comprising administering to a subject an effective amount of a composition of an anti-PD-L1 antibody and anlotinib. The present application further provides a use of the composition of an anti-PD-L1 antibody and anlotinib in the treatment of biliary tract tumors.

[0043] As a further aspect of the present application, there is provided a kit for treating biliary tract tumors, comprising a pharmaceutical composition of an anti-PD-L1 antibody, a pharmaceutical composition of anlotinib, and instructions for the combined use of the anti-PD-L1 antibody and anlotinib in treating biliary tract tumors.

[0044] As a further aspect of the present application, there is further provided an anti-PD-L1 antibody for treating biliary tract tumors.The present application further provides a method for treating biliary tract tumors, comprising administering to a subject an effective amount of an anti-PD-L1 antibody of the present disclosure.The present application further provides a use of an anti-PD-L1 antibody in treating biliary tract tumors.The present application further provides a use of an anti-PD-L1 antibody in the manufacture of a medicament for treating biliary tract tumors.

[0045] COMBINED PHARMACEUTICAL COMPOSITION FOR TREATING LIVER CANCER In one embodiment of the present application, there is provided a combination pharmaceutical composition for treating liver cancer, comprising an anti-PD-L1 antibody and anlotinib.

[0046] In some embodiments of the present application, the combination pharmaceutical composition comprises a pharmaceutical composition of an anti-PD-L1 antibody and a pharmaceutical composition of anlotinib.

[0047] In some embodiments of the present application, the combination pharmaceutical composition is packaged in a kit, and the kit includes instructions for the combined use of an anti-PD-L1 antibody and anlotinib in the treatment of liver cancer.

[0048] In some embodiments, a combination pharmaceutical composition for treating liver cancer is provided, comprising a pharmaceutical composition comprising 600-2400 mg of an anti-PD-L1 antibody and a pharmaceutical composition of anlotinib in a single dose of 6 mg, 8 mg, 10 mg, and / or 12 mg, where the pharmaceutical composition comprising the anti-PD-L1 antibody is in a single dose or in multiple doses.

[0049] In some embodiments, a combination pharmaceutical composition for treating liver cancer is provided, comprising a pharmaceutical composition comprising 600-2400 mg of an anti-PD-L1 antibody in multiple doses, and a pharmaceutical composition comprising anlotinib in a single dose of 6 mg, 8 mg, 10 mg, and / or 12 mg.

[0050] In some embodiments, a combination pharmaceutical composition for treating liver cancer is provided, comprising an anti-PD-L1 antibody and anlotinib in a weight ratio of (0.35-29):1, preferably (3.5-29):1, more preferably (3.5-14.5):1, and most preferably (7-14.5):1. Here, the anti-PD-L1 antibody and anlotinib may be packaged separately or together. Anlotinib may also be packaged in multiple equal portions (e.g., 2 equal portions, 7 equal portions, 14 equal portions, 28 equal portions, or more).

[0051] In some embodiments, there is provided a combination pharmaceutical composition for treating liver cancer, comprising a pharmaceutical composition of an anti-PD-L1 antibody and a pharmaceutical composition of anlotinib, where the anti-PD-L1 antibody is formulated to be suitable for administering to a patient a single dose or multiple doses of 600-2400 mg of the anti-PD-L1 antibody at the first administration, and the pharmaceutical composition of anlotinib is formulated to be suitable for administering to a patient a single dose of 6 mg, 8 mg, 10 mg, and / or 12 mg of anlotinib every day for 14 days.

[0052] In some embodiments, pharmaceutical compositions of anti-PD-L1 antibodies include those containing 10-60 mg / mL anti-PD-L1 antibody, and those containing anti-PD-L1 antibodies in single doses of 6 mg, 8 mg, 10 mg, and / or 12 mg. and a pharmaceutical composition containing anlotinib, which is an effective therapeutic agent for treating liver cancer.

[0053] In some embodiments, there is provided a combination pharmaceutical composition for treating liver cancer, comprising a pharmaceutical composition of an anti-PD-L1 antibody comprising 10 mg / mL anti-PD-L1 antibody, and a pharmaceutical composition comprising anlotinib in a single dose of 8 mg and / or 10 mg.

[0054] In some embodiments, there is provided a combination pharmaceutical composition for treating liver cancer, comprising a pharmaceutical composition comprising 1200 mg of an anti-PD-L1 antibody in multiple doses, and a pharmaceutical composition comprising anlotinib in a single dose of 8 mg and / or 10 mg.

[0055] As a further aspect of the present application, there is provided a use of the combination pharmaceutical composition in the manufacture of a medicament for treating liver cancer. The present application further provides a method for treating liver cancer, comprising administering to a subject an effective amount of the combination pharmaceutical composition of the present disclosure. The present application further provides a use of the combination pharmaceutical composition in treating liver cancer. In some embodiments, the combination pharmaceutical composition comprises an anti-PD-L1 humanized monoclonal antibody and anlotinib.

[0056] In a further aspect of the present application, there is provided a use of a composition of an anti-PD-L1 antibody and anlotinib in the manufacture of a medicament for treating liver cancer.The present application further provides a method of treating liver cancer, comprising administering to a subject an effective amount of a composition of an anti-PD-L1 antibody and anlotinib.The present application further provides a use of a composition of an anti-PD-L1 antibody and anlotinib in treating liver cancer.

[0057] In a further aspect of the present application, there is provided a kit for treating liver cancer, the kit comprising a pharmaceutical composition of an anti-PD-L1 antibody, a pharmaceutical composition of anlotinib, and instructions for using the anti-PD-L1 antibody and anlotinib in combination to treat liver cancer.

[0058] As a further aspect of the present application, there is further provided an anti-PD-L1 antibody for treating liver cancer.The present application further provides a method for treating liver cancer, comprising administering to a subject an effective amount of an anti-PD-L1 antibody of the present disclosure.The present application further provides a use of an anti-PD-L1 antibody in treating liver cancer.The present application further provides a use of an anti-PD-L1 antibody in the manufacture of a medicament for treating liver cancer.

[0059] COMBINATION PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER - Patent application In one embodiment of the present application, there is provided a combination pharmaceutical composition for treating triple-negative breast cancer, comprising an anti-PD-L1 antibody and anlotinib.

[0060] In some embodiments of the present application, the combination pharmaceutical composition comprises a pharmaceutical composition of an anti-PD-L1 antibody and a pharmaceutical composition of anlotinib.

[0061] In some embodiments of the present application, the combination pharmaceutical composition is packaged in a kit, and the kit includes instructions for the combination of a PD-L1 antibody and anlotinib in the treatment of triple-negative breast cancer.

[0062] In some embodiments, there is provided a combination pharmaceutical composition for treating triple-negative breast cancer, comprising a pharmaceutical composition comprising 600-2400 mg of an anti-PD-L1 antibody and a pharmaceutical composition comprising anlotinib in a single dose of 6 mg, 8 mg, 10 mg, and / or 12 mg, wherein the pharmaceutical composition comprising the anti-PD-L1 antibody is in a single dose or in multiple doses.

[0063] In some embodiments, a combination pharmaceutical composition for treating triple-negative breast cancer is provided, comprising a pharmaceutical composition comprising 600-2400 mg of an anti-PD-L1 antibody in multiple doses, and a pharmaceutical composition comprising anlotinib in a single dose of 6 mg, 8 mg, 10 mg, and / or 12 mg.

[0064] In some embodiments, a combination pharmaceutical composition for treating triple-negative breast cancer is provided, comprising an anti-PD-L1 antibody and anlotinib in a weight ratio of (0.35-29):1, preferably (3.5-29):1, more preferably (3.5-14.5):1, and most preferably (7-14.5):1, where the anti-PD-L1 antibody and anlotinib may be packaged separately or together. Additionally, anlotinib may be packaged in multiple equal portions (e.g., 2 equal portions, 7 equal portions, 14 equal portions, 28 equal portions, or more).

[0065] In some embodiments, there is provided a combination pharmaceutical composition for treating triple negative breast cancer, comprising a pharmaceutical composition of an anti-PD-L1 antibody and a pharmaceutical composition of anlotinib, where the anti-PD-L1 antibody is formulated to be suitable for administering to a patient a single dose or multiple doses of 600-2400 mg of the anti-PD-L1 antibody at the first administration, and the pharmaceutical composition of anlotinib is formulated to be suitable for administering to a patient a single dose of 6 mg, 8 mg, 10 mg, and / or 12 mg of anlotinib every day for 14 days.

[0066] In some embodiments, there is provided a combination pharmaceutical composition for treating triple-negative breast cancer, comprising a pharmaceutical composition of an anti-PD-L1 antibody comprising 10-60 mg / mL anti-PD-L1 antibody, and a pharmaceutical composition comprising anlotinib in a single dose of 6 mg, 8 mg, 10 mg, and / or 12 mg.

[0067] In some embodiments, there is provided a combination pharmaceutical composition for treating triple-negative breast cancer, comprising a pharmaceutical composition of an anti-PD-L1 antibody comprising 10 mg / mL anti-PD-L1 antibody, and a pharmaceutical composition comprising anlotinib in a single dose of 8 mg and / or 10 mg.

[0068] In some embodiments, there is provided a combination pharmaceutical composition for treating triple negative breast cancer, comprising a pharmaceutical composition comprising 1200 mg of an anti-PD-L1 antibody in multiple doses, and a pharmaceutical composition comprising anlotinib in a single dose of 8 mg and / or 10 mg.

[0069] As a further aspect of the present application, there is provided a use of a combination pharmaceutical composition in the manufacture of a medicament for treating triple-negative breast cancer. The present application further provides a method for treating triple-negative breast cancer, comprising administering to a subject an effective amount of a combination pharmaceutical composition of the present disclosure. The present application further provides a use of a combination pharmaceutical composition in the treatment of triple-negative breast cancer. In some embodiments, the combination pharmaceutical composition comprises an anti-PD-L1 humanized monoclonal antibody and anlotinib.

[0070] As a further aspect of the present application, there is provided a use of a composition of an anti-PD-L1 antibody and anlotinib in the manufacture of a medicament for treating triple-negative breast cancer.The present application further provides a method of treating triple-negative breast cancer, comprising administering to a subject an effective amount of a composition of an anti-PD-L1 antibody and anlotinib.The present application further provides a use of a composition of an anti-PD-L1 antibody and anlotinib in treating triple-negative breast cancer.

[0071] In a further aspect of the present application, there is provided a kit for treating triple-negative breast cancer, the kit comprising a pharmaceutical composition of an anti-PD-L1 antibody, a pharmaceutical composition of anlotinib, and instructions for combining the anti-PD-L1 antibody and anlotinib in treating triple-negative breast cancer.

[0072] As a further aspect of the present application, there is further provided an anti-PD-L1 antibody for treating triple-negative breast cancer.The present application further provides a method of treating triple-negative breast cancer, comprising administering to a subject an effective amount of an anti-PD-L1 antibody of the present disclosure.The present application further provides a use of an anti-PD-L1 antibody in treating triple-negative breast cancer.The present application further provides a use of an anti-PD-L1 antibody in the manufacture of a medicament for treating triple-negative breast cancer.

[0073] COMBINATION PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LUNG CANCER In one embodiment of the present application, there is provided a combination pharmaceutical composition for treating lung cancer, comprising an anti-PD-L1 antibody and anlotinib.

[0074] In some embodiments of the present application, the combination pharmaceutical composition comprises a pharmaceutical composition of an anti-PD-L1 antibody and a pharmaceutical composition of anlotinib.

[0075] In some embodiments of the present application, the combination pharmaceutical composition is packaged in a kit, and the kit includes instructions for the combination of a PD-L1 antibody and anlotinib in the treatment of lung cancer.

[0076] In some embodiments, there is provided a combination pharmaceutical composition for treating lung cancer comprising a pharmaceutical composition comprising 600-2400 mg of an anti-PD-L1 antibody and a pharmaceutical composition comprising anlotinib in a single dose of 6 mg, 8 mg, 10 mg, and / or 12 mg, where the pharmaceutical composition comprising the anti-PD-L1 antibody is in a single dose or in multiple doses.

[0077] In some embodiments, a combination pharmaceutical composition for treating lung cancer is provided, comprising a pharmaceutical composition comprising 600-2400 mg of an anti-PD-L1 antibody in multiple doses, and a pharmaceutical composition comprising anlotinib in a single dose of 6 mg, 8 mg, 10 mg, and / or 12 mg.

[0078] In some embodiments, there is provided a combination pharmaceutical composition for treating lung cancer, comprising a pharmaceutical composition of an anti-PD-L1 antibody and a pharmaceutical composition of anlotinib, where the anti-PD-L1 antibody is formulated to be suitable for administration to a patient of one or more doses of 600-2400 mg of the anti-PD-L1 antibody at the first administration, and the pharmaceutical composition of anlotinib is formulated to be suitable for administration to a patient of one dose of 6 mg, 8 mg, 10 mg, and / or 12 mg of anlotinib every day for 14 days.

[0079] In some embodiments, there is provided a combination pharmaceutical composition for treating lung cancer, comprising a pharmaceutical composition of an anti-PD-L1 antibody comprising 10-60 mg / mL anti-PD-L1 antibody, and a pharmaceutical composition comprising anlotinib in a single dose of 6 mg, 8 mg, 10 mg, and / or 12 mg.

[0080] In some embodiments, a combination pharmaceutical composition for treating lung cancer is provided, comprising an anti-PD-L1 antibody and anlotinib in a weight ratio of (0.35-29):, preferably (3.5-29):, more preferably (3.5-14.5):1, and most preferably (7-14.5):1, where the anti-PD-L1 antibody and anlotinib may be packaged separately or together, and anlotinib may be packaged in multiple equal portions (e.g., 2 equal portions, 7 equal portions, 14 equal portions, 28 equal portions or more).

[0081] In some embodiments, a pharmaceutical composition of an anti-PD-L1 antibody comprising 10 mg / mL anti-PD-L1 antibody and a pharmaceutical composition comprising anlotinib at a single dose of 8 mg and / or 10 mg. The present invention provides a combination pharmaceutical composition for treating lung cancer, comprising:

[0082] In some embodiments, there is provided a combination pharmaceutical composition for treating lung cancer comprising a pharmaceutical composition comprising 1200 mg of an anti-PD-L1 antibody in multiple doses, and a pharmaceutical composition comprising anlotinib in a single dose of 8 mg and / or 10 mg.

[0083] As a further aspect of the present application, there is provided a use of a combination pharmaceutical composition in the manufacture of a medicament for treating lung cancer.The present application further provides a method for treating lung cancer, comprising administering to a subject an effective amount of a combination pharmaceutical composition of the present disclosure.The present application further provides a use of a combination pharmaceutical composition in the treatment of lung cancer.The combination pharmaceutical composition comprises an anti-PD-L1 humanized monoclonal antibody and anlotinib.

[0084] As a further aspect of the present application, there is provided a use of a composition of an anti-PD-L1 antibody and anlotinib in the manufacture of a medicament for treating lung cancer.The present application further provides a method of treating lung cancer, comprising administering to a subject an effective amount of a composition of an anti-PD-L1 antibody and anlotinib.The present application further provides a use of a composition of an anti-PD-L1 antibody and anlotinib in treating lung cancer.

[0085] In a further aspect of the present application, there is provided a kit for treating lung cancer, the kit comprising a pharmaceutical composition of an anti-PD-L1 antibody, a pharmaceutical composition of anlotinib, and instructions for using the anti-PD-L1 antibody and anlotinib in combination to treat lung cancer.

[0086] As a further aspect of the present application, there is further provided an anti-PD-L1 antibody for treating lung cancer.The present application further provides a method of treating lung cancer, comprising administering to a subject an effective amount of an anti-PD-L1 antibody of the present disclosure.The present application further provides a use of an anti-PD-L1 antibody in treating lung cancer.The present application further provides a use of an anti-PD-L1 antibody in the manufacture of a medicament for treating lung cancer.

[0087] Administration / treatment regimen of combined pharmaceutical compositions In some embodiments of the application, in the above uses or methods of treatment, the anti-PD-L1 antibody and anlotinib may be administered simultaneously, sequentially or at intervals, each in the form of a pharmaceutical composition.

[0088] In some embodiments of the present application, in the uses or methods of treatment, the anti-PD-L1 antibody and anlotinib are administered at separate intervals. In some embodiments, the antibody and anlotinib are administered separately using the same or different treatment regimens. In some embodiments, they are administered separately using different treatment regimens.

[0089] In some embodiments of the present application, in the uses or methods of treatment, the anti-PD-L1 antibody may be administered once a week (q1w), every two weeks (q2w), every three weeks (q3w), or every four weeks (q4w). In a particular embodiment, the anti-PD-L1 antibody is administered once every three weeks. In some embodiments, the anti-PD-L1 antibody is administered at a dose of 600-2400 mg each time.

[0090] The anlotinib may be administered at doses of 6 mg, 8 mg, 10 mg, or 12 mg once daily on a regimen of 2 weeks on treatment and 1 week off.

[0091] In some embodiments, the treatment periods for the anti-PD-L1 antibody and the anlotinib may be the same or different, hi certain embodiments, the treatment periods for the anti-PD-L1 antibody and the anlotinib are the same, e.g., one treatment period is 1 week, 2 weeks, 3 weeks, or 4 weeks.

[0092] In some embodiments of the application, the use or method of treatment comprises a 21 day treatment period, with the PD-L1 antibody being administered on the first day of each period and anlotinib being administered daily on days 1 through 14 of each period. In one particular embodiment, the PD-L1 antibody is administered once on the first day of each period and anlotinib is administered once daily on days 1 through 14 of each period.

[0093] In some embodiments of the application, in the uses or methods of treatment, the anti-PD-L1 antibody is administered at a dose of 0.01 to 40 mg / kg, 0.1 to 30 mg / kg, 0.1 to 20 mg / kg, 0.1 to 15 mg / kg, 0.1 to 10 mg / kg, 1 to 15 mg / kg, 1 to 20 mg / kg, 1 to 3 mg / kg, 3 to 10 mg / kg, 3 to 15 mg / kg, 3 to 20 mg / kg, 3 to 30 mg / kg g, 10 to 20 mg / kg, and 15 to 20 mg / kg, or may be administered to a subject at a dose of 60 mg to 2400 mg, 90 mg to about 1800 mg, 120 mg to 1500 mg, 300 mg to 900 mg, 600 mg to 900 mg, 300 mg to 1200 mg, 600 mg to 1200 mg, or 900 mg to 1200 mg.

[0094] In some embodiments of the above-mentioned uses or methods of treatment, one treatment period is 21 days with 1200 mg of the anti-PD-L1 antibody administered on the first day of each period and 6 mg, 8 mg, 10 mg and / or 12 mg of anlotinib administered daily on days 1-14 of each period.

[0095] In some embodiments of the present application, a subject is administered the anti-PD-L1 antibody and anlotinib in a weight ratio of (0.35-29):1, preferably (3.5-29):1, more preferably (3.5-14.5):1, and most preferably (7-14.5):1, over a 3 week treatment period, and the anti-PD-L1 antibody and anlotinib are administered in a single dose and multiple doses, respectively.

[0096] Pharmaceutical compositions of anti-PD-L1 antibodies In some embodiments of the present application, a single dose of the anti-PD-L1 antibody pharmaceutical composition contains 300 mg or 600 mg of anti-PD-L1 antibody.

[0097] In some embodiments of the present application, the total dose of the anti-PD-L1 antibody pharmaceutical composition is 600-2400 mg. In some embodiments, the total dose of the anti-PD-L1 antibody pharmaceutical composition is selected from the group consisting of 600 mg, 900 mg, 1200 mg, 1500 mg, 1800 mg, 2100 mg, 2400 mg, and a range formed by any of the foregoing values. In some embodiments, the total dose of the anti-PD-L1 antibody pharmaceutical composition is preferably 600-2100 mg or 900 mg-1500 mg.

[0098] In some embodiments of the present application, the pharmaceutical composition of the anti-PD-L1 antibody comprises one or more of a buffer, a tonicity adjusting agent, a stabilizer, and / or a surfactant. In particular, the pharmaceutical composition of the anti-PD-L1 antibody comprises 1-150 mg / mL of an anti-PD-L1 antibody (e.g., mAb), 3-50 mM of a buffer, 2-150 mg / mL of a tonicity adjusting agent / stabilizer, and 0.01-0.8 mg / mL of a surfactant, and has a pH of about 4.5-6.8.

[0099] In some embodiments of the present application, the anti-PD-L1 antibody pharmaceutical composition has an anti-PD-L1 mAb concentration of about 5-150 mg / mL, preferably about 10-60 mg / mL, and more preferably about 10-30 mg / mL (w / v). In certain embodiments, the anti-PD-L1 mAb concentration is about 10 mg / mL, about 20 mg / mL, about 30 mg / mL, about 40 mg / mL, about 50 mg / mL, about 60 mg / mL, about 70 mg / mL, about 80 mg / mL, about 90 mg / mL, about 100 mg / mL, about 110 mg / mL, or about The concentration of the anti-PD-L1 monoclonal antibody is about 10 mg / mL (w / v). In some embodiments, the concentration of the anti-PD-L1 mAb is about 30 mg / mL (w / v). In some embodiments, the concentration of the anti-PD-L1 mAb is about 60 mg / mL (w / v). In some embodiments, the concentration of the anti-PD-L1 mAb is about 60 mg / mL (w / v).

[0100] In some embodiments of the present application, the buffer is a histidine salt buffer. The histidine salt buffer has a concentration of about 5-30 mM, preferably about 10-25 mM, more preferably about 10-20 mM, and most preferably about 10-15 mM. In some specific embodiments, the histidine salt buffer has a concentration of about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, or about 30 mM. In some embodiments, the histidine salt buffer has a concentration of about 10 mM. In some embodiments, the histidine salt buffer has a concentration of about 15 mM. In some embodiments, the histidine salt buffer has a concentration of about 20 mM. Here, the histidine salt buffer comprises histidine and hydrochloric acid.

[0101] In some embodiments of the present application, the tonicity adjusting / stabilizing agent is about 20-150 mg / mL sucrose, preferably about 40-100 mg / mL sucrose, more preferably about 60-80 mg / mL (w / v) sucrose. In some specific embodiments, the concentration of the sucrose is about 40 mg / mL, 50 mg / mL, 60 mg / mL, 70 mg / mL, 80 mg / mL, 90 mg / mL, or 100 mg / mL. In some specific embodiments, the concentration of the sucrose is about 60 mg / mL. In some specific embodiments, the concentration of the sucrose is about 70 mg / mL. In some specific embodiments, the concentration of the sucrose is about 80 mg / mL. In some specific embodiments, the concentration of the sucrose is about 90 mg / mL.

[0102] In some embodiments of the present application, the surfactant is selected from the group consisting of polysorbate 80, polysorbate 20, and poloxamer 188, preferably polysorbate 80 and polysorbate 20, more preferably polysorbate 80. In some embodiments, the concentration of the surfactant is about 0.05-0.6 mg / mL, preferably about 0.1-0.4 mg / mL, more preferably about 0.2-0.3 mg / mL (w / v).

[0103] In some embodiments of the present application, the surfactant is about 0.01-0.8 mg / mL (w / v) of polysorbate 80 or polysorbate 20. In some specific embodiments, the surfactant is about 0.05-0.6 mg / mL of polysorbate 80, preferably about 0.1-0.4 mg / mL of polysorbate 80, more preferably about 0.2-0.3 mg / mL of polysorbate 80, and most preferably about 0.2 mg / mL of polysorbate 80. In some embodiments, the amount of polysorbate 80 in the pharmaceutical composition is about 0.1 mg / mL, 0.2 mg / mL, 0.3 mg / mL, 0.4 mg / mL, 0.5 mg / mL, or 0.6 mg / mL, preferably, the amount of polysorbate 80 in the pharmaceutical composition is about 0.2 mg / mL, 0.3 mg / mL, 0.4 mg / mL, or 0.5 mg / mL, more preferably, the amount of polysorbate 80 in the pharmaceutical composition is about 0.2 mg / mL, 0.3 mg / mL, or 0.4 mg / mL, and most preferably, the amount of polysorbate 80 in the pharmaceutical composition is about 0.2 mg / mL. In some embodiments, the amount of polysorbate 80 in the pharmaceutical composition is about 0.1 mg / mL. In some embodiments, the amount of polysorbate 80 in the pharmaceutical composition is about 0.2 mg / mL. In some embodiments, the amount of polysorbate 80 in the pharmaceutical composition is about 0.2 mg / mL. In some embodiments, the amount of polysorbate 80 in the pharmaceutical composition is about 0.3 mg / mL. In some embodiments, the amount of polysorbate 80 in the pharmaceutical composition is about 0.4 mg / mL. In some embodiments, the amount of polysorbate 80 in the pharmaceutical composition is about 0.5 mg / mL.

[0104] In some embodiments of the present application, the pH of the aqueous solution of the pharmaceutical composition is 4.0 to 6.8, preferably 4.5 to 6.5, more preferably 5.5 to 6.0, and most preferably 5.5. In some embodiments, the pH of the aqueous solution of the pharmaceutical composition is about 4.5, about 4.8, about 5.0, about 5.2, about 5.4, about 5.5, about 5.6, about 5.8, or about 6.0, preferably about 5.0, about 5.2, about 5.4, about 5.5, or about 5.6, and more preferably about 5.5. In some embodiments, the pH of the aqueous solution of the pharmaceutical composition is about 5.0. In some embodiments, the pH of the aqueous solution of the pharmaceutical composition is about 5.2. In some embodiments, the pH of the aqueous solution of the pharmaceutical composition is about 5.4. In some embodiments, the pH of the aqueous solution of the pharmaceutical composition is about 5.5. In some embodiments, the pH of the aqueous solution of the pharmaceutical composition is about 5.6. In some embodiments, the pH of the aqueous solution of the pharmaceutical composition is about 5.8. In some embodiments, the aqueous solution of the pharmaceutical composition has a pH of about 6.0.

[0105] In certain embodiments of the application, the pharmaceutical composition comprises (a) about 20 mg / mL (w / v) of an anti-PD-L1 antibody, (b) about 70 mg / mL (w / v) of sucrose, (c) about 0.1 mg / mL (w / v) of polysorbate 80, (d) about 20 mM histidine, and (e) optionally, a suitable amount of hydrochloric acid to adjust the pH of the composition to about 5.0. In one particular embodiment of the application, the pharmaceutical composition comprises (a) about 20 mg / mL (w / v) of an anti-PD-L1 mAb, (b about 70 mg / mL (w / v) of sucrose, (c) about 0.1 mg / mL (w / v) of polysorbate 80, (d) about 20 mM histidine, and (e) optionally, a suitable amount of hydrochloric acid to adjust the pH of the composition to about 5.0.

[0106] In another specific embodiment of the application, the pharmaceutical composition comprises: (a) about 10 mg / mL (w / v) anti-PD-L1 antibody; (b) about 80 mg / mL (w / v) sucrose; (c) about 0.2 mg / mL (w / v) polysorbate 80; (d) about 10 mM histidine; and (e) optionally, a suitable amount of hydrochloric acid to adjust the pH of the composition to about 5.5.

[0107] In another specific embodiment of the application, the pharmaceutical composition comprises: (a) about 50 mg / mL (w / v) anti-PD-L1 antibody; (b) about 80 mg / mL (w / v) sucrose; (c) about 0.3 mg / mL (w / v) polysorbate 80; (d) about 10 mM histidine; and (e) optionally, a suitable amount of hydrochloric acid to adjust the pH of the composition to about 5.5.

[0108] In another specific embodiment of the application, the pharmaceutical composition comprises: (a) about 100 mg / mL (w / v) anti-PD-L1 antibody; (b) about 80 mg / mL (w / v) sucrose; (c) about 0.5 mg / mL (w / v) polysorbate 80; (d) about 10 mM histidine; and (e) optionally, a suitable amount of hydrochloric acid to adjust the pH of the composition to about 5.5.

[0109] In another specific embodiment of the application, the pharmaceutical composition comprises: (a) about 30 mg / mL (w / v) anti-PD-L1 antibody; (b) about 80 mg / mL (w / v) sucrose; (c) about 0.2 mg / mL (w / v) polysorbate 80; (d) about 10 mM histidine; and (e) optionally, a suitable amount of hydrochloric acid to adjust the pH of the composition to about 5.5.

[0110] In another specific embodiment of the application, the pharmaceutical composition comprises: (a) about 60 mg / mL (w / v) anti-PD-L1 antibody; (b) about 80 mg / mL (w / v) sucrose; (c) about 0.2 mg / mL (w / v) polysorbate 80; (d) about 10 mM histidine; and (e) optionally, a suitable amount of hydrochloric acid to adjust the pH of the composition to about 5.5.

[0111] In another specific embodiment of the application, the pharmaceutical composition comprises: (a) about 10 mg / mL (w / v) anti-PD-L1 antibody; (b) about 70 mg / mL (w / v) sucrose; (c) about 0.4 mg / mL (w / v) polysorbate 80; (d) about 20 mM histidine; and (e) optionally, an amount of acetic acid to adjust the pH of the composition to about 6.5.

[0112] In another specific embodiment of the application, the pharmaceutical composition comprises: (a) about 10 mg / mL (w / v) of anti-PD-L1 mAb; (b) about 80 mg / mL (w / v) of sucrose; (c) about 0.2 mg / mL (w / v) of polysorbate 80; (d) about 20 mM histidine; and (e) optionally, a suitable amount of hydrochloric acid to adjust the pH of the composition to about 5.5.

[0113] In another specific embodiment of the present application, the pharmaceutical composition is an aqueous injectable formulation, including, but not limited to, an aqueous formulation that is not lyophilized or an aqueous formulation that is reconstituted from a lyophilized powder. In some embodiments, the pharmaceutical composition is a lyophilized formulation. The lyophilized formulation refers to a formulation produced by subjecting an aqueous solution to a lyophilization process, in which the material is first frozen, then the amount of solvent is reduced by sublimation (primary drying process) and then desorption (secondary drying process) to a level that does not support biological activity or chemical reaction. The lyophilized formulation of the present application may be dried by other methods known in the art, such as spray drying, bubble drying.

[0114] Pharmaceutical Compositions of Anlotinib In some embodiments of the present application, a single dose of the pharmaceutical composition of anlotinib comprises 6 mg, 8 mg, 10 mg, or 12 mg of anlotinib.

[0115] In some embodiments of the present application, the total dose of the pharmaceutical composition of anlotinib administered during each treatment period comprises 84-168 mg, according to a period of 2 weeks of treatment and 1 week of discontinuation. In some embodiments, the total dose of the pharmaceutical composition of anlotinib is selected from the group consisting of 84 mg, 112 mg, 140 mg, 168 mg, and a range formed by any of the foregoing values. In some embodiments, the total dose of the pharmaceutical composition of anlotinib preferably comprises 112 mg to 168 mg.

[0116] Anti-PD-L1 antibody In some embodiments of the application, the anti-PD-L1 antibody is an antibody described in WO2016022630 or CN107001463A.

[0117] In some embodiments of the application, the anti-PD-L1 antibody comprises a heavy chain CDR1 region that has at least 80% (e.g., 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) homology to the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:4; a heavy chain CDR2 region that has at least 80% (e.g., 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) homology to the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:5; a heavy chain CDR3 region having at least 80% (e.g., 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) homology to the amino acid sequence shown in SEQ ID NO:7 or SEQ ID NO:10; a light chain CDR1 region having 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% homology to the amino acid sequence set forth in SEQ ID NO:8 or SEQ ID NO:11; 9 or 12.

[0118] In some embodiments of the application, the anti-PD-L1 antibody comprises the following amino acid sequences: a heavy chain CDR1 region selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:4, a heavy chain CDR2 region selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:5, a heavy chain CDR3 region selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:6, a light chain CDR1 region selected from the group consisting of SEQ ID NO:7 and SEQ ID NO:10, a light chain CDR2 region selected from the group consisting of SEQ ID NO:8 and SEQ ID NO:11, and a light chain CDR3 region selected from the group consisting of SEQ ID NO:9 and SEQ ID NO:12.

[0119] In some embodiments of the application, the isolated anti-PD-L1 antibodies described herein comprise a heavy chain CDR1 region having the amino acid sequence set forth in SEQ ID NO:1, a heavy chain CDR2 region having the amino acid sequence set forth in SEQ ID NO:2, a heavy chain CDR3 region having the amino acid sequence set forth in SEQ ID NO:3, a light chain CDR1 region having the amino acid sequence set forth in SEQ ID NO:7, a light chain CDR2 region having the amino acid sequence set forth in SEQ ID NO:8, and a light chain CDR3 region having the amino acid sequence set forth in SEQ ID NO:9.

[0120] Each of the CDR regions described herein and their variants described above can specifically recognize and bind to PD-L1, and effectively block signaling between PD-L1 and PD-1.

[0121] In some embodiments of the application, the anti-PD-L1 antibodies comprise a heavy chain variable region that is at least 80% (e.g., 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the amino acid sequence set forth in SEQ ID NO:13 or SEQ ID NO:14, and a light chain variable region that is at least 80% (e.g., 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to the amino acid sequence set forth in SEQ ID NO:15 or SEQ ID NO:16.

[0122] In some embodiments of the present application, the anti-PD-L1 antibody comprises a heavy chain variable region set forth in SEQ ID NO:13, and a light chain variable region set forth in SEQ ID NO:15.

[0123] In some embodiments of the present application, the anti-PD-L1 antibody comprises a heavy chain variable region set forth in SEQ ID NO:14, and a light chain variable region set forth in SEQ ID NO:16.

[0124] In some embodiments of the present application, the anti-PD-L1 antibody comprises a heavy chain amino acid sequence set forth in SEQ ID NO:17, and a light chain amino acid sequence set forth in SEQ ID NO:18.

[0125] In some embodiments of the present application, the anti-PD-L1 antibody comprises a heavy chain amino acid sequence set forth in SEQ ID NO:19, and a light chain amino acid sequence set forth in SEQ ID NO:20.

[0126] In some embodiments of the present application, the anti-PD-L1 antibody comprises a heavy chain amino acid sequence set forth in SEQ ID NO:21, and a light chain amino acid sequence set forth in SEQ ID NO:18.

[0127] In one specific embodiment, the anti-PD-L1 humanized mAb of the disclosure is SEQ ID NO:1, SEQ ID NO: 2, and one or more conservatively substituted variants selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:21. Anti-PD-L1 humanized mAbs containing such conservatively substituted variants retain the ability to specifically recognize and bind to PD-L1.

[0128] In some embodiments of the application, the anti-PD-L1 antibody may be an IgG1 or IgG4 antibody.

[0129] In some embodiments of the present application, the anti-PD-L1 antibody is an IgG1 antibody, hi some embodiments, the anti-PD-L1 antibody is a glycosylated IgG1 antibody.

[0130] In some embodiments of the application, the anti-PD-L1 antibody comprises a heavy chain complementarity determining region (CDR) selected from the group consisting of heavy chain CDRs derived from 13C5 and 5G11 antibodies, and a light chain CDR selected from the group consisting of light chain CDRs derived from 13C5 and 5G11 antibodies.In one embodiment, the anti-PD-L1 antibody of the disclosure comprises a heavy chain variable region selected from the group consisting of heavy chain variable regions of ch5G11-hIgG1, ch5G11-hIgG4, ch13C5-hIgG1, and ch13C5-hIgG4 chimeric antibodies, and a light chain variable region selected from the group consisting of light chain variable regions of ch5G11-hIgG1, ch5G11-hIgG4, ch13C5-hIgG1, and ch13C5-hIgG4 chimeric antibodies. In one embodiment, the anti-PD-L1 antibody of the disclosure comprises a heavy chain variable region selected from the group consisting of hu13C5-hIgG1, hu13C5-hIgG4, hu5G11-hIgG1, and hu5G11-hIgG4 humanized antibody heavy chain variable regions, and a light chain variable region selected from the group consisting of hu13C5-hIgG1, hu13C5-hIgG4, hu5G11-hIgG1, and hu5G11-hIgG4 humanized antibody light chain variable regions. Reference may be made to the following disclosure in patent literature WO2016022630 or CN107001463A: The HCDR1 sequence of 13C5, ch13C5-hIgG1, ch13C5-hIgG4, hu13C5-hIgG1 or hu13C5-hIgG4 is SYGMS (SEQ ID NO: 4), the HCDR2 sequence is SISSGGSTYYPDSVKG (SEQ ID NO: 5), the HCDR3 sequence is GYDSGFAY (SEQ ID NO: 6), the LCDR1 sequence is ASQSVSTSSSSFMH (SEQ ID NO: 10), the LCDR2 sequence is YASNLES (SEQ ID NO: 11) and the LCDR3 sequence is QHSWEIPYT (SEQ ID NO: 12). and for 5G11, ch5G11-hIgG1, ch5G11-hIgG4, hu5G11-hIgG1 or hu5G11-hIgG4, the HCDR1 sequence is TYGVH (SEQ ID NO: 1), the HCDR2 sequence is VIWRGVTTDYNAAFMS (SEQ ID NO: 2), the HCDR3 sequence is LGFYAMDY (SEQ ID NO: 3), the LCDR1 sequence is KASQSVSNDVA (SEQ ID NO: 7), the LCDR2 sequence is YAANRYT (SEQ ID NO: 8), and the LCDR3 sequence is QQDYTSPYT (SEQ ID NO: 9).

[0131] In some embodiments of the present application, the anti-PD-L1 antibody in the drug combination may be one or more. As used herein, the term "multiple" may mean one or more, for example, two, three, four, five or more. For example, in some embodiments of the present application, the anti-PD-L1 antibody is selected from the group consisting of antibodies comprising a heavy chain variable region set forth in SEQ ID NO: 13 and a light chain variable region set forth in SEQ ID NO: 15, or selected from the group consisting of antibodies comprising a heavy chain variable region set forth in SEQ ID NO: 14 and a light chain variable region set forth in SEQ ID NO: 16, or selected from the group consisting of combinations thereof. In other examples, the anti-PD-L1 antibody is selected from the group consisting of antibodies comprising a heavy chain amino acid sequence set forth in SEQ ID NO: 17 and a light chain amino acid sequence set forth in SEQ ID NO: 18, or selected from the group consisting of antibodies comprising a heavy chain amino acid sequence set forth in SEQ ID NO: 19 and a light chain amino acid sequence set forth in SEQ ID NO: 20, or selected from the group consisting of antibodies comprising a heavy chain amino acid sequence set forth in SEQ ID NO: 21 and a light chain amino acid sequence set forth in SEQ ID NO: 18. or any combination of the foregoing.

[0132] Anlotinib As used herein, anlotinib free base has the chemical name 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine and the following structural formula: [ka]

[0133] In the present application, the anlotinib includes its non-salt form (e.g., free base), and further includes its pharmaceutically acceptable salt.All non-salt forms or salts are included in the scope of protection of the present application.For example, the pharmaceutically acceptable salt of anlotinib can be hydrochloride or dihydrochloride.The dosage of anlotinib or its salt in the present application is calculated based on the molecular weight of anlotinib, unless otherwise specified.

[0134] Biliary Tumors In some embodiments of the present application, the biliary tumor is a biliary adenocarcinoma. In some embodiments of the present application, the biliary tumor includes gallbladder cancer (GBC), intrahepatic cholangiocarcinoma (IHCC), and extrahepatic cholangiocarcinoma (EHCC). In some embodiments of the present application, the extrahepatic cholangiocarcinoma includes hilar cholangiocarcinoma (also known as Klatskin tumor) and distal cholangiocarcinoma. In some embodiments of the present application, the biliary tumor includes gallbladder adenocarcinoma, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma.

[0135] In some embodiments of the present application, the biliary tumor comprises a biliary tumor that is not resectable for surgery, late stage or metastatic. In some embodiments of the present application, the biliary tumor comprises a gallbladder cancer that is not resectable for surgery, late stage or metastatic adenocarcinoma type, intrahepatic cholangiocarcinoma type, or extrahepatic cholangiocarcinoma type. In some embodiments of the present application, the patient with biliary tumor has received chemotherapy and has failed the treatment. In some embodiments of the present application, the patient with biliary tumor has failed the first-line chemotherapy that was received.

[0136] Liver cancer In some embodiments of the present application, the liver cancer is hepatocellular carcinoma (HCC). In some embodiments of the present application, the liver cancer is selected from primary hepatocellular carcinoma. In some embodiments of the present application, the liver cancer is late stage and / or metastatic hepatocellular carcinoma. In some embodiments, the hepatocellular carcinoma is unresectable hepatocellular carcinoma. In some embodiments, the hepatocellular carcinoma is hepatocellular carcinoma that has undergone localized treatment and has failed or is not suitable for localized treatment, the localized treatment including, but not limited to, ablation (including, but not limited to, radiofrequency ablation, cryoablation, percutaneous ethanol injection therapy, microwave ablation), radiation therapy, and / or hepatic arterial chemoembolization. In some embodiments, the hepatocellular carcinoma is hepatocellular carcinoma that has failed treatment with sorafenib and / or lenvatinib.

[0137] Triple-negative breast cancer In some embodiments of the present application, the subject with triple-negative breast cancer has undergone surgery, chemotherapy and / or radiation therapy. In certain embodiments, the subject with triple-negative breast cancer has undergone first-line chemotherapy. In certain embodiments, the subject with triple-negative breast cancer has undergone anthracycline and / or taxane drug therapy. In certain embodiments, the subject with triple-negative breast cancer has undergone at least first-line systemic therapy, and has undergone anthracycline and / or taxane drugs.

[0138] lung cancer In some embodiments of the present application, the lung cancer is non-small cell lung cancer. In some embodiments, the lung cancer comprises lung squamous cell carcinoma or lung adenocarcinoma. In some embodiments, the lung cancer is late stage lung cancer. In some embodiments, the lung cancer is EGFR or ALK wild type non-small cell lung cancer. In some embodiments, the lung cancer is selected from the group consisting of late stage squamous non-small cell lung cancer and late stage adenocarcinoma non-small cell lung cancer. In some embodiments, the lung cancer is selected from EGFR or ALK wild type squamous non-small cell lung cancer and EGFR or ALK wild type adenocarcinoma non-small cell lung cancer. In some embodiments, the lung cancer is BRaf or EGFR mutant non-small cell lung cancer, such as BRAF p.V600E, EGFR del and / or EGFR-T790M non-small cell lung cancer.

[0139] In some embodiments, the lung cancer patient has been treated with chemotherapy, hi some embodiments, the lung cancer is late-stage (stage IIIB and / or IV) lung cancer that has been treated with first-line standard chemotherapy and has failed or is intolerant to chemotherapy.

[0140] In the present application, the chemotherapy includes, but is not limited to, one or more of platinum-based drugs, fluoropyrimidine derivatives, camptothecin, taxanes, vinblastine, anthracyclines, antibiotics, podophyllum, antineoplastic agents, and antimetabolites, examples of which include platinum-based drugs (e.g., oxaliplatin, cisplatin, carboplatin, nedaplatin, dicycloplatin), fluoropyrimidine derivatives (e.g., gemcitabine, capecitabine, ancitabine, fluorouracil, diflazine, doxifluridine, tegafur, carmofur, trifluridine), taxanes (e.g., paclitaxel, albumin-bound paclitaxel, docetaxel), camptothecin and its analogs (e.g., camptothecin, hydroxycamptothecin, 9- Aminocamptothecin, 7-ethylcamptothecin, irinotecan, topotecan), vinca alkaloids (vinorelbine, vinblastine, vincristine, vindesine, vinflunine), anthracyclines (epirubicin, doxorubicin, daunorubicin, pirarubicin, amrubicin, idarubicin, mitoxantrone, aclarubicin, valrubicin, zorubicin, pixantrone), pemetrexed, carmustine, melphalan, etoposide, teniposide, mitomycin, ifosfamide, cyclophosphamide, azacitidine, methotrexate, bendamustine, liposomal doxorubicin, actinomycin D (dactinomycin), bleomycin, pingyangmycin, temozolomide, dacarbazine, These include, but are not limited to, one or more of: peplomycin, eribulin, plinabulin, sapacitabine, treosulfan, 153Sm-EDTMP, tegafur-gimeracil-oteracil potassium, and encequidar.

[0141] Administration The following is not intended to limit the methods of administration of the drug combinations of the present disclosure.

[0142] The components of the pharmaceutical compositions of the present disclosure can be administered independently or some or all of the components can be co-administered by a variety of suitable routes, including, but not limited to, oral or parenteral administration (by intravenous, intramuscular, topical or subcutaneous routes). In some embodiments, the components of the pharmaceutical combinations of the present disclosure can be administered independently or some or all of the components can be co-administered by means such as oral administration or injection (e.g., intravenous or intraperitoneal injection).

[0143] The components of the pharmaceutical compositions of the present application may be administered independently or some or all of the components may be administered simultaneously in any suitable dosage form, including, but not limited to, tablets, troches, pills, capsules (e.g., hard capsules, soft capsules, enteric capsules, microcapsules), elixirs, granules, syrups, injectables (intramuscular, intravenous, intraperitoneal), granules, emulsions, suspensions, solutions, dispersions, and sustained release formulations for oral or parenteral administration.

[0144] The components of the pharmaceutical combinations of the present disclosure can be formulated independently, or some or all of the components can be co-formulated with pharma- ceutically acceptable carriers and / or excipients.

[0145] The drug combinations of the present disclosure may further comprise other drugs, hi one embodiment, the other drugs may be cancer drugs known in the art.

[0146] Effect of the Invention In general, the use of the combined pharmaceutical compositions of the present disclosure provides the following: (1) the combination has a more effective effect on inhibiting tumor growth and even eliminating tumors than administration of either drug alone; (2) The dose is smaller than that of either drug in the combination administered alone; (3) be better tolerated by patients and have fewer side effects and / or complications compared with either drug administered alone; (4) The disease control rate of treated patients was high. (5) longer survival times (e.g., median survival time, progression-free survival, overall survival) for treated patients; (6) Compared with standard chemotherapy, treated patients survive longer (e.g., median survival, progression-free survival, overall survival), (7) Prolonged duration of response (DOR); and / or (8) Compared with administration of either drug alone, the combination provides superior efficacy in treating biliary tumors, liver cancer, triple-negative breast cancer, and / or lung cancer, and exhibits superior anti-tumor synergistic effects.

[0147] Definitions and Explanations Unless otherwise specified, the following terms used in this application have the following meanings. Certain terms are to be understood in their ordinary sense in the art, rather than being considered as open or unclear unless specifically defined. When trade names are mentioned, the corresponding product or its active ingredient is to be understood in the ordinary sense in the art. is intended to refer to an ingredient.

[0148] As used herein, the term "combination pharmaceutical composition" refers to a combination of two or more active ingredients (each administered as the active ingredient itself or each administered as a derivative, prodrug or composition, such as a pharma- ceutically acceptable salt or ester) administered simultaneously or sequentially. As used herein, the terms "combination pharmaceutical composition," "pharmaceutical composition," and "drug combination" are used interchangeably.

[0149] As used herein, the term "antibody" refers to a binding protein having at least one antigen-binding domain. The antibodies and fragments thereof of the present disclosure may be intact antibodies or any fragments thereof. Thus, the antibodies and fragments thereof of the present disclosure include monoclonal antibodies or fragments thereof, antibody variants or fragments thereof, and immunoconjugates. Examples of antibody fragments include Fab fragments, Fab' fragments, F(ab')2 fragments, Fv fragments, isolated CDR regions, single-chain Fv molecules (scFv), Fd fragments, and other antibody fragments known in the art. Antibodies and fragments thereof may further include recombinant polypeptides, fusion proteins, and bispecific antibodies. The anti-PD-L1 antibodies and fragments thereof of the present disclosure may be of the IgG1, IgG2, IgG3, or IgG4 isotype. The term "isotype" refers to the class of antibody encoded by the heavy chain constant region genes. In one embodiment, the anti-PD-L1 antibodies and fragments thereof of the present disclosure are of the IgG1 or IgG4 isotype. The PD-1 antibodies and fragments thereof of the present application may be derived from any species, including, but not limited to, mouse, rat, rabbit, primate, llama, and human. The PD-L1 antibodies and fragments thereof may be chimeric, humanized, or intact human antibodies. In one embodiment, the anti-PD-L1 antibody is an antibody produced from a hybridoma cell line derived from a mouse. Thus, in one embodiment, the anti-PD-L1 antibody is a murine antibody. In another embodiment, the anti-PD-L1 antibody is a chimeric antibody. In another embodiment, the chimeric antibody is a mouse-human chimeric antibody. In another embodiment, the antibody is a humanized antibody. In another embodiment, the antibody is derived from a murine antibody and humanized.

[0150] A "humanized antibody" is an antibody that comprises complementarity determining regions (CDRs) derived from a non-human antibody and framework and constant regions derived from a human antibody. For example, an anti-PD-L1 antibody of the present disclosure may comprise CDRs derived from one or more murine antibodies and human framework and constant regions. Thus, in one embodiment, a humanized antibody of the present disclosure binds to the same epitope on PD-L1 as the murine antibody from which the CDRs of the humanized antibody are derived. Exemplary humanized antibodies are disclosed herein. Other anti-PD-L1 antibodies or variants thereof comprising the heavy and light chain CDRs of the present disclosure can be generated using any human framework sequence and are also included in the present application. In one embodiment, framework sequences suitable for use in the present application include those that are structurally similar to the framework sequences of the present disclosure. Further modifications to the framework regions may be made to improve the properties of the antibodies of the present disclosure. Such further framework modifications may include chemical modifications, point mutations to reduce immunogenicity or remove T-cell epitopes, or back mutations to residues in the original germline sequence. In some embodiments, such modifications include modifications corresponding to the mutations exemplified herein, including backmutation to germline sequences. For example, in one embodiment, one or more amino acids in the human framework regions of the VH and / or VL of a humanized antibody according to the present invention are backmutated to the corresponding amino acid in the parent mouse antibody. For example, in the case of the VH and VL of humanized 5G11 and humanized 13C5 antibodies, several sites of the framework amino acids of the template human antibody described above may be backmutated to the corresponding amino acid sequences in the mouse 5G11 and 13C5 antibodies. In one embodiment, the amino acids at positions 53, 60, and / or 67 of the light chain variable region are backmutated to the corresponding amino acids at said positions in the mouse 5G11 or 13C5 light chain variable region. In another embodiment, the heavy chain variable region is backmutated to the corresponding amino acids at said positions in the mouse 5G11 or 13C5 light chain variable region. are backmutated to the corresponding amino acids at said positions in the murine 5G11 or 13C5 heavy chain variable region. In one embodiment, the humanized 5G11 antibody comprises a light chain variable region in which the amino acid at position 60 is mutated from Ser (S) to Asp (D) and the amino acid at position 67 is mutated from Ser (S) to Tyr (Y), and a heavy chain variable region in which the amino acid at position 24 is mutated from Phe (F) to Val (V), the amino acid at position 49 is mutated from Ala (A) to Gly (G), the amino acid at position 73 is mutated from Thr (T) to Asn (N), and the amino acid at position 83 is mutated from Thr (T) to Asn (N). In one embodiment, the humanized 13C5 antibody comprises a light chain variable region in which the amino acid at position 53 has been mutated from Tyr (Y) to Lys (K), and a heavy chain variable region in which the amino acid at position 28 has been mutated from Thr (T) to Ile (I), the amino acid at position 30 has been mutated from Ser (S) to Arg (R), the amino acid at position 49 has been mutated from Ser (S) to Ala (A), and the amino acid at position 94 has been mutated from Tyr (Y) to Asp (D). Additional or alternative back mutations may be made in the framework regions of the humanized antibodies of the present disclosure to improve the properties of the antibody. The present application further includes humanized antibodies that bind PD-L1 and include framework modifications that correspond to any of the exemplary modifications of suitable framework sequences described herein, as well as other framework modifications that improve the properties of the antibody in other ways.

[0151] The present application provides an isolated antibody or fragment thereof that binds to PD-L1, wherein the antibody is produced by a hybridoma selected from the group consisting of hybridomas designated herein as 13C5 and 5G11. Thus, the present application further includes hybridomas 13C5 and 5G11, as well as any hybridoma that produces an antibody of the present disclosure. The present application further provides an isolated polynucleotide encoding the antibody or fragment thereof of the present disclosure. The present application further includes an expression vector comprising the isolated polynucleotide, and a host cell comprising the expression vector.

[0152] An "isolated antibody" refers to an antibody that is substantially free of other antibodies with different antigenic specificities (e.g., an isolated antibody that specifically binds PD-1 is substantially free of antibodies that specifically bind to antigens other than PD-1). However, an isolated antibody that specifically binds PD-1 may have cross-reactivity with other antigens (e.g., PD-1 molecules from different species). An isolated antibody may also be substantially free of other cellular material and / or chemicals.

[0153] The term "monoclonal antibody (mAb)" refers to a non-naturally occurring preparation of individual molecular component antibody molecules (i.e., antibody molecules that are substantially identical in nucleic acid sequence and that display a single binding specificity and affinity for a particular epitope). A mAb is an example of an isolated antibody. mAbs can be produced by hybridoma technology, recombinant technology, genetic engineering technology, or other techniques known to those of skill in the art.

[0154] The antibodies and antigen-binding fragments thereof of the present disclosure are specific for PD-L1. In one embodiment, the antibodies or fragments thereof are specific for PD-L1. In one embodiment, the antibodies and fragments thereof of the present disclosure bind to human or primate PD-L1 but do not bind to PD-L1 from other mammals. In another embodiment, the antibodies and fragments thereof do not bind to mouse PD-L1. The terms "human PD-L1", "hPD-L1", "huPD-L1", etc. are used interchangeably herein and refer to human PD-L1 and variants or isotypes of human PD-L1. "Specific" and "specificity" refer to the fact that the antibodies and fragments thereof bind to PD-L1 with greater affinity than to other targets.

[0155] The terms "treat" and "treatment" generally refer to a desired The term "treatment" refers to obtaining a pharmacological and / or physiological effect associated with a disease. The effect may be therapeutic in terms of partially or completely stabilizing or curing a disease and / or side effects associated with the disease. As used herein, "treat" and "treatment" encompass any treatment of a patient's disease, including (a) inhibiting a symptom of the disease, i.e., preventing the progression of the disease, or (b) ameliorating a symptom of the disease, i.e., relieving the disease or condition.

[0156] The term "effective amount" refers to an amount of a compound of the present disclosure to (i) treat a particular disease, condition, or disorder, (ii) reduce, ameliorate, or eliminate one or more symptoms of a particular disease, condition, or disorder, or (iii) prevent or delay the onset of one or more symptoms of a particular disease, condition, or disorder described herein. The amount of an active agent (e.g., an antibody or compound of the present disclosure) that constitutes a "therapeutically effective amount" varies depending on a variety of factors, such as the individual's condition, age, sex, and weight, and the ability of the drug or drug combination to elicit a desired response in the individual. The effective amount may be determined from the knowledge of one of ordinary skill in the art or from the contents of the present disclosure.

[0157] The terms "administer" and "administration" refer to the physical introduction of a composition containing an agent into a subject using any of a variety of methods and delivery systems known to those of skill in the art. Routes of administration of immune checkpoint inhibitors (e.g., anti-PD-1 antibodies or anti-PD-L1 antibodies) include intravenous, intramuscular, subcutaneous, intraperitoneal, intrathecal, or other parenteral routes of administration (e.g., injection or infusion). As used herein, the term "parenteral administration" refers to routes of administration other than enteral and topical administration, which are generally performed by injection, non-limiting examples of which include intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, intrasternal injection and infusion, and in vivo electroporation. In some embodiments, the immune checkpoint inhibitor (e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody) is administered parenterally, and in some embodiments, orally. Other parenteral routes include topical, epidermal, or mucosal routes of administration, such as intranasal, intravaginal, rectal, sublingual, and topical. Administration may be single or multiple times and / or over one or more extended periods of time.

[0158] The term "dose" refers to the dose administered to a patient without consideration of the patient's weight or body surface area (BSA), e.g., a 60 kg human and a 100 kg human receive the same dose of antibody (e.g., 240 mg of an anti-PD-1 antibody).

[0159] As used herein, the term "weight-based dose" refers to the dose to be administered to a patient calculated based on the patient's weight. For example, if a patient weighing 60 kg requires 3 mg / kg of anti-PD-1 antibody, an appropriate amount of anti-PD-1 antibody (180 mg) may be extracted at one time from a fixed dose formulation of anti-PD-1 antibody.

[0160] Anlotinib can be administered by various routes, including, but not limited to, oral, parenteral, intraperitoneal, intravenous, intraarterial, transdermal, sublingual, intramuscular, rectal, transbuccal, intranasal, inhalation, vaginal, intraocular, topical, subcutaneous, intraadipose, intraarticular, and intrathecal. In certain embodiments, it is administered orally. The dosage of anlotinib may be determined based on the severity of the disease, the response of the disease, treatment-related toxicity, and the age or health status of the patient. For example, the daily dosage of anlotinib is 2 mg to 20 mg. In some embodiments, the daily dosage of anlotinib or a pharma- ceutically acceptable salt thereof may be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 mg. Anlotinib may be administered once or multiple times daily. In some embodiments, anlotinib is administered once daily as an oral solid formulation.

[0161] The treatment plan of anlotinib may be determined comprehensively based on the activity, toxicity, and patient tolerability of the drug. Preferably, anlotinib is administered at intervals. The interval administration includes a treatment period and a discontinuation period, and anlotinib is administered once or multiple times daily during the treatment period. For example, the ratio calculated by the number of days of the treatment period and the discontinuation period is 2:0.5 to 2:5, preferably 2:0.5 to 2:3, more preferably 2:0.5 to 2:2, and even more preferably 2:0.5 to 2:1. In some embodiments, the treatment is administered for 2 weeks and interrupted for 2 weeks. In some embodiments, the treatment is administered for 2 weeks and interrupted for 1 week. In some embodiments, the treatment is administered for 5 days and interrupted for 2 days. For example, anlotinib may be administered once daily at a dose of 6 mg, 8 mg, 10 mg, or 12 mg for 2 weeks and interrupted for 1 week.

[0162] The term "pharmacologically acceptable" refers to compounds, materials, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human or animals without undue toxicity, irritation, allergic response, or other problem or complication, and are commensurate with a reasonable benefit / risk ratio.

[0163] The term "pharmaceutical acceptable salt" includes salts formed by base ions and free acids, and salts formed by acid ions and free bases, such as hydrochloride, hydrobromide, nitrate, sulfate, phosphate, formate, acetate, trifluoroacetate, fumarate, oxalate, maleate, citrate, succinate, mesylate, benzenesulfonate, p-methylbenzenesulfonate, preferably hydrochloride, hydrobromide, sulfate, formate, acetate, trifluoroacetate, fumarate, maleate, mesylate, p-methylbenzenesulfonate, sodium salt, potassium salt, ammonium salt, amino acid salt, etc. In the present application, when forming a pharmaceutical acceptable salt, the molar ratio of the free acid to the base ion is about 1:0.5 to 1:5, preferably 1:0.5, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, or 1:8.

[0164] As used herein, the terms "subject" and "patient" are used interchangeably. In some embodiments, the term "subject" or "patient" is a mammal. In some embodiments, the subject or patient is a mouse. In some embodiments, the subject or patient is a human.

[0165] The term "about" is understood to include a range of three standard deviations from the mean, or a range of tolerance in a particular field. In some embodiments, the term "about" is understood as a variation that does not exceed 0.5. The term "about" modifies the value that follows it. For example, "about 1, 2, and 3" means "about 1," "about 2," and "about 3."

[0166] As used herein, the terms "combined use" or "use in combination" refer to two or more active agents being administered to a subject in a single formulation, in any order, simultaneously or sequentially.

[0167] The term "single dose" refers to the smallest unit package containing a given amount of drug, e.g., a box of seven capsules, each capsule being a single dose, or a vial of injectable drug being a single dose. As used herein, the terms "single dose" and "unit dose" have the same meaning and are used interchangeably.

[0168] The term "multiple doses" consists of a plurality of single doses.

[0169] The term "pharmaceutical composition" refers to a mixture of one or more of the disclosed active ingredients or combinations thereof and a pharma- ceutical acceptable excipient. This is done to make the drug combination easier to administer.

[0170] In this specification, unless otherwise stated, the terms "comprise," "comprises," "comprising," and their equivalents are open-ended statements and mean that the recited elements, components, and steps may include elements, components, and steps that are not specifically recited.

[0171] The present specification incorporates by reference in its entirety patents, patent applications, and other existing publications for purposes of explanation and disclosure. These publications are provided because they were published prior to the filing date of this application. Any statement of publication dates for these documents or statements regarding their contents is based on the information available to applicant and does not constitute any statement as to the accuracy of the publication dates or contents of these documents. Moreover, the incorporation of these publications in this specification does not constitute an admission that such publications are common general knowledge in the art, regardless of country or region. EXAMPLES

[0172] The present application will now be further described with reference to examples, but the scope of the present application is not limited to these examples. All reagents used in the present application are commercially available products and can be used without further purification. In the examples, anti-PD-L1 antibodies were prepared according to the method described in WO2016022630, and after affinity chromatography, an eluate containing the antibody was obtained using a conventional antibody purification method.

[0173] Example 1: Clinical Trial of Biliary Tumors 1.1 Inclusion Criteria 1) Patients must be aged 18 years or older, have an ECOG performance status score of 0-1, and have an expected survival time of 3 months or longer. 2) Patients with histologically or pathologically confirmed unresectable or metastatic bile duct cancer, including intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and gallbladder cancer (GBC). 3) Patients have at least one measurable lesion (RECIST 1.1).

[0174] 4) Patients who have received first-line chemotherapy but have failed the treatment. Chemotherapy failure is defined as disease progression during or after the last treatment, or intolerance to toxicity or side effects during treatment. 5) Laboratory tests must meet the following criteria: Blood test: hemoglobin (Hb) ≥ 80g / L (no blood transfusion within 14 days), absolute neutrophil count (ANC) ≥ 1.5 × 10 9 / L, platelet (PLT) ≧75×10 9 / L, biochemical test: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≦2.5×ULN (≦5×ULN in case of liver metastasis), serum total bilirubin (TBIL) ≦2×ULN (≦3×ULN in case of Gilbert syndrome), serum creatinine (Cr) ≦1.5×ULN, and creatinine clearance rate >50 μmol / L, blood coagulation function: activated partial thromboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT) ≦1.5×ULN; Doppler ultrasound test: left ventricular ejection fraction (LVEF) ≧50%. 6) Female subjects must agree to use contraception (e.g., intrauterine device [IUD], contraceptive pills, or condoms) during the study and for 6 months after completion, have a negative serum or urine pregnancy test within 7 days prior to participation, and be non-breastfeeding. Male subjects must agree to use contraception during the study and for 6 months after completion. 7) Patients willingly participate in this study, sign informed consent, and are in good compliance.

[0175] 1.2 Test Drug Anti-PD-L1 antibody injection hu5G11-hIgG1: 1,200 mg of anti-PD-L1 antibody injection (100 mg / 10 mL) was diluted with saline to 250 mL, and the diluted drug was administered by infusion in 60 ± 5 minutes. After the infusion was completed, the tube was flushed with saline as a routine medical procedure, and the drug was administered once every 21 days, i.e., a treatment period of 21 days. Anlotinib hydrochloride capsules (active ingredient: anlotinib dihydrochloride): 10 mg of anlotinib hydrochloride capsules were orally administered on an empty stomach 5 minutes before or after the start of anti-PD-L1 antibody infusion, for 2 weeks followed by 1 week off, for a treatment period of 21 days. Dosage: 12mg, 10mg, and 8mg.

[0176] 1.3 Evaluation Criteria The disease status will be assessed based on RECIST 1.1 / irRECIST. RECIST 1.1 evaluation criteria will be the main focus.

[0177] 1.4 Endpoints Response rate (ORR) = (complete response (CR) + partial response (PR)) Antitumor efficacy endpoints: progression-free survival (PFS), disease control rate (DCR = CR + PR + stable disease (SD)), overall survival (OS), stable disease (SD), PR (partial response), etc.

[0178] [Table 1]

[0179] Dosage: Patients C01002, C01007, and C01017 were administered a combination of 1200mg of anti-PD-L1 antibody hu5G11-hIgG1 injection and 10mg of anlotinib hydrochloride capsule. Patients C01009 and C01021 were administered a combination of 1200mg of anti-PD-L1 antibody hu5G11-hIgG1 injection and 12mg of anlotinib hydrochloride capsule. Patient C01006 was administered a combination of 1200mg of anti-PD-L1 antibody hu5G11-hIgG1 injection and 12mg of anlotinib hydrochloride capsule, and the anlotinib hydrochloride capsule was later reduced to 10mg (in the examples of this application, the amount of anlotinib hydrochloride capsule was calculated based on the weight of anlotinib therein).

[0180] Patient Diagnosis and Treatment History: Patient C01002: Left hemihepatectomy + hepatomegaly lymphadenectomy. Metastasis after 2 periods of radiotherapy and DC-CIK cell treatment, disease progression after 3 radioknife treatments and 4 periods of GP treatment (gemcitabine + cisplatin). Patient C01006: Immunohistochemistry: CA19.9 (2+), CK18 (3+), CK19 (2+), CK7 (2+), Ki-67 (+20~30%). PD after 6 periods of albumin paclitaxel + tegafur-gimeracil-oteracil potassium capsule treatment, then PD (disease progression) after interventional therapy.

[0181] Patient C01007: Immunohistochemistry: CA19.9(2+), CD34(2+), CK18(2+), CK19(2+), CK7(2+), Ki-67(+10%). Gemcitabine + capecitabine combination therapy, myelosuppression. After disease progression, oxaliplatin + tegafur-gimeracil-oteracil potassium capsules q3w. Then albumin paclitaxel + apatinib. Patient C01009: Immunohistochemistry: PCX(+), CK(+), CK19(partially+), AFP(+), CD56(+), Ki-67(+10%), gemcitabine 1.4g d1 / 8 + cisplatin 40mg d2,3, intolerable.

[0182] Patient C01017: Immunohistochemistry: CK18(3+), CK19(3+), CK7(3+), CA19.9(1+), AFP(1+), Ki-67(+30%). GC treatment (gemcitabine 1.6g d1 / 1.4g d8 + tegafur-gimeracil-oteracil 60mg bid po / 3w) was intolerable after 4 periods. Patient C01021: Tegafur-gimeracil-oteracil potassium + oxaliplatin combination, 6 periods.

[0183] Example 2: Liver cancer clinical trial 2.1 Inclusion Criteria 1) Patients must be aged 18 years or older, have an ECOG performance status score of 0-1, and have a projected survival time of 3 months or longer. 2) Late-stage hepatocellular carcinoma confirmed by histopathological or cytological examination (Barcelona Hepatocellular Carcinoma Stage C, or refractory Stage B for which treatment is not suitable). 3) Patients have at least one measurable lesion (RECIST 1.1). 4) The liver cancer patients were not receiving immunotherapy.

[0184] 5) Clinical test eligibility requirements: Blood test: Hemoglobin (Hb) ≥ 80g / L (no blood transfusion within 14 days), absolute neutrophil count (ANC) ≥ 1.5 x 10 9 / L, platelet (PLT) ≧75×10 9 / L, biochemical test: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≦2.5×ULN (≦5×ULN for patients with liver metastasis), serum total bilirubin (TBIL) ≦2×ULN (≦3×ULN for patients with Gilbert syndrome), serum creatinine (Cr) ≦1.5×ULN and creatinine clearance rate >50 μmol / L, blood coagulation function: activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT) ≦1.5×ULN, Doppler ultrasound test: left ventricular ejection fraction (LVEF) ≧50%. 6) Female subjects must agree to use contraception (e.g., intrauterine device [IUD], contraceptive pills, or condoms) during the study and for 6 months after completion, have a negative serum or urine pregnancy test within 7 days prior to participation, and be non-lactating. Male subjects must agree to use contraception during the study and for 6 months after completion. 7) Patients willingly participate in this study, sign informed consent, and are in good compliance.

[0185] 2.2 Test Drug Anti-PD-L1 antibody hu5G11-hIgG1 injection: 1200 mg of anti-PD-L1 antibody injection (100 mg / 10 mL) was diluted with saline to 250 mL, and the diluted drug was administered by infusion over 60 ± 5 minutes. After the infusion was completed, the tube was flushed with saline as a routine medical procedure, and the drug was administered once every 21 days. Anlotinib hydrochloride capsules (active ingredient: anlotinib dihydrochloride): 10 mg of anlotinib hydrochloride capsules were orally administered on an empty stomach 5 minutes before or after the start of anti-PD-L1 antibody infusion, for 2 weeks followed by 1 week off, for a treatment period of 21 days. Dosage: 12mg, 10mg, and 8mg.

[0186] 2.3 Evaluation Criteria The disease status will be assessed based on RECIST 1.1 / irRECIST. RECIST 1.1 evaluation criteria will be the main focus.

[0187] 2.4 Endpoints Response rate (ORR) = (complete response (CR) + partial response (PR)) Antitumor efficacy endpoints: progression-free survival (PFS), disease control rate (DCR = CR + PR + stable disease (SD)), overall survival (OS), stable disease (SD), partial response (PR), etc.

[0188] [Table 2]

[0189] Dosage profile: Patients C01003, C01005, C01015, and C01020 were administered a combination of 1200mg anti-PD-L1 antibody hu5G11-hIgG1 injection and 10mg anlotinib hydrochloride capsule. Patient C01013 was administered a combination of 1200mg anti-PD-L1 antibody hu5G11-hIgG1 injection and 12mg anlotinib hydrochloride capsule. Patient C01019 was administered a combination of 1200mg anti-PD-L1 antibody hu5G11-hIgG1 injection and 10mg anlotinib hydrochloride capsule, with the anlotinib hydrochloride capsule later reduced to 8mg.

[0190] Patient Diagnosis and Treatment History: Patient C01003: Immunohistochemistry: Arg-1(1+), CD34(3+), CK18(2+), GPC3(1+), Hepatocyte(3+), Ki-67(+80%), CD31(3+), intolerance to sorafenib. Patient C01005: Disease progression after sorafenib treatment.

[0191] Patient C01013: Disease progression after surgery and oral administration of lenvatinib capsules. Patient C01020: Intolerance to oral lenvatinib. Patients C01019 and C01015: had not received standard treatment.

[0192] Example 3: Triple-negative breast cancer clinical trial Example 1. Clinical Trials 3.1 Inclusion Criteria 1) Age 18-75 years, ECOG performance status score 0-1, expected survival time 3 months or longer. 2) Histologically or cytologically confirmed recurrent or metastatic triple-negative breast cancer, where triple-negative breast cancer is defined as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (Her-2) negative. ER / PR negative was defined as follows: ER negative was defined as ER<1% positive, and PR negative was defined as PR<1% positive. Her-2 negative was defined as Her-2(-) or (1+) by immunohistochemistry, where Her-2(2+) patients must undergo FISH testing with a negative result, and Her-2(-) or (1+) patients may selectively undergo FISH testing, but the result must be negative. 3) Patients have at least one measurable lesion (RECIST 1.1). 4) Patients have received at least one first-line systemic therapy with anthracyclines and / or taxanes and have had disease progression after the last treatment. Recurrence or disease progression during or within 6 months after the end of treatment is considered a treatment failure.

[0193] 5) Clinical test eligibility requirements: Blood test: Hemoglobin (Hb) ≥ 80g / L (no blood transfusion within 14 days), absolute neutrophil count (ANC) ≥ 1.5 x 10 9 / L, platelet (PLT) ≧75×10 9 / L, biochemical test: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≦2.5×ULN (≦5×ULN for patients with liver metastasis), serum total bilirubin (TBIL) ≦1.5×ULN (≦3×ULN for patients with Gilbert syndrome), serum creatinine (Cr) ≦1.5×ULN and creatinine clearance rate >50 μmol / L, blood coagulation function: activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT) ≦1.5×ULN, Doppler ultrasound test: left ventricular ejection fraction (LVEF) ≧50%. 6) Female subjects must agree to use contraception (e.g., intrauterine device [IUD], contraceptive pills, or condoms) during the study and for 6 months after completion, have a negative serum or urine pregnancy test within 7 days prior to participation, and be non-lactating. Male subjects must agree to use contraception during the study and for 6 months after completion. 7) Patients willingly participate in this study, sign informed consent, and are in good compliance.

[0194] 3.2 Test Drug Anti-PD-L1 antibody hu5G11-hIgG1 injection: 1200 mg of anti-PD-L1 antibody injection (100 mg / 10 mL) was diluted with saline to 250 mL, and the diluted drug was administered by infusion over 60 ± 5 minutes. After the infusion was completed, the tube was flushed with saline as a routine medical procedure, and the drug was administered once every 21 days. Anlotinib hydrochloride capsules (active ingredient: anlotinib dihydrochloride): 10 mg of anlotinib hydrochloride capsules were orally administered on an empty stomach 5 minutes before or after the start of anti-PD-L1 antibody infusion, for 2 weeks followed by 1 week off, for a treatment period of 21 days. Dosage: 12mg, 10mg, and 8mg.

[0195] 3.3 Evaluation Criteria The disease status will be evaluated based on RECIST 1.1 / irRECIST. 1.1 Evaluation criteria are the main focus.

[0196] 3.4 Endpoints Response rate (ORR) = (complete response (CR) + partial response (PR)) Antitumor effect indicators: progression-free survival (PFS), disease control rate (DCR = CR + PR + stable disease (SD)), overall survival (OS), etc.

[0197] [Table 3]

[0198] Dosage profile: Patients C01001 and C01003 received a combination of 1200 mg of the anti-PD-L1 antibody hu5G11-hIgG1 injection and 10 mg of anlotinib hydrochloride capsules. Patients C01004, C01005, C01006, C01007, C01008, and C01009 received a combination of 1200 mg of the anti-PD-L1 antibody hu5G11-hIgG1 injection and 12 mg of anlotinib hydrochloride capsules.

[0199] Patient Diagnosis and Treatment History: Patient C01001: Invasive breast cancer in the left breast with lymph node metastasis. She has undergone radical surgery, chemotherapy (AT treatment (doxorubicin + docetaxel, 3 periods), AC treatment (doxorubicin + cyclophosphamide, 3 periods), GP treatment (gemcitabine + carboplatin, 4 periods)), and radiation therapy (100Gy, 50Gy) in that order. Patient C03003: Invasive breast cancer in the right breast with lymph node metastasis. She has undergone radical surgery, chemotherapy (pirarubicin + cyclophosphamide + docetaxel, 8 periods), and radiation therapy in that order. Patient C01004: Suspected invasive breast cancer in the right breast, lung metastasis, and bone metastasis. Has undergone radical surgery, chemotherapy (AC-T treatment (pirarubicin + cyclophosphamide + paclitaxel, 8 periods), capecitabine (6 periods), TC treatment (docetaxel + carboplatin, 8 periods), docetaxel (2 periods)), and radiation therapy (50Gy) in that order. Patient C01005: Invasive breast cancer in the right breast with lung and liver metastases. He has undergone radical surgery, chemotherapy (AC-T treatment (pirarubicin + cyclophosphamide + paclitaxel, 8 periods), TX + nimotuzumab (docetaxel + capecitabine, 6 periods), GP treatment (gemcitabine + cisplatin, 4 periods), gemcitabine + carboplatin (1 period), and IM. P4297 capsule (PARP inhibitor) and radiation therapy were administered sequentially.

[0200] Patient C01006: Invasive breast cancer in the right breast. She has undergone radical surgery, chemotherapy (TEC treatment (paclitaxel + epirubicin + cyclophosphamide), GP treatment (gemcitabine + cisplatin, 6 periods), TX treatment (docetaxel + capecitabine, 1 period)), and radiation therapy in that order. Patient C01007: Invasive breast cancer in the left breast with lymph node metastasis. She has undergone radical surgery, chemotherapy (TC treatment (paclitaxel + carboplatin, 6 periods), paclitaxel + capecitabine (3 periods)), and radiation therapy (223.4 Gy) in that order. Patient C01008: Invasive breast cancer in the left breast. She has undergone radical surgery, chemotherapy (EC-T treatment (epirubicin + cyclophosphamide + paclitaxel, 8 periods)), and radiation therapy in that order. Patient C01009: Invasive ductal carcinoma in the left breast with lymph node metastasis. She has undergone radical surgery and chemotherapy (TAC treatment (pirarubicin + cyclophosphamide + paclitaxel, 6 periods), paclitaxel (9 periods), carboplatin (1 period)) in that order.

[0201] Example 4: Lung Cancer Clinical Trials 4.1 Inclusion Criteria 1) Patients must be aged 18 years or older, have an ECOG performance status score of 0-1, and have an expected survival time of 3 months or longer. 2) Histologically or cytologically confirmed non-small cell lung cancer. 3) Patients who have received at least first-line standard chemotherapy but have failed or are intolerant to chemotherapy and have late-stage disease (stage IIIB / IV) and at least one measurable lesion by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). 4) PD-L1 expression is positive in the tumor (tumor proportion score TPS ≥ 1%). Tissue Samples: Formalin-fixed, paraffin-embedded tumor samples will be used for PD-L1 analysis. Tissue samples must be received and evaluated by a central service provider prior to randomized enrollment. Fine needle aspirates will not be used. Core needle biopsies, biopsy tissue resection samples, or resected tissue were acceptable.

[0202] 5) Normal major organ function meets the following criteria: a) Blood test: Hemoglobin (Hb) ≥ 90g / L (no blood transfusion within 14 days), absolute neutrophil count (ANC) ≥ 1.5 × 10 9 / L, platelet (PLT) ≧80×10 9 / L. b) Biochemical tests: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver metastases), serum total bilirubin (TBIL) ≤ 1.5 x ULN (≤ 3 x ULN for patients with Gilbert syndrome), serum creatinine (Cr) ≤ 1.5 x ULN, or calculated creatinine clearance rate ≥ 50 mL / min. Creatinine clearance rate: Ccr = (140 - age) x body weight (kg) / 72 x Scr (mg / dL). Ccr=[(140-age)×weight (kg) / [0.818×Scr(μmol / L)] For women, multiply the calculated rate by 0.85; 1 mg / dL = 88.41 μmol / L. c) Blood coagulation: activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT) ≦ 1.5 × ULN. 6) Female subjects must agree to use contraception (e.g., intrauterine device [IUD], contraceptive pills, or condoms) during the study and for 6 months after completion, have a negative serum or urine pregnancy test within 7 days prior to participation, and be non-lactating. Sexual subjects must agree to use contraceptive devices during the study and within 6 months after completion of the study. 7) Patients willingly participate in this study, sign informed consent, and are in good compliance.

[0203] 4.2 Exclusion criteria 1) Previously received anlotinib hydrochloride, other PD-1 / PD-L1 antibodies, or other immunotherapy against PD-1 / PD-L1 antibodies. 2) Severe hypersensitivity reactions are observed after administration of other monoclonal antibodies. 3) Currently or within the past 5 years, have other malignant tumors (excluding cured basal cell carcinoma or cervical cancer). 4) Active autoimmune disease or history of autoimmune disease (e.g., including but not limited to autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, and nephritis. Asthma patients who required medical treatment with bronchodilators were not eligible. However, patients with vitiligo, psoriasis, and alopecia not requiring systemic treatment, type I diabetes mellitus patients with effectively suppressed progression, and hypothyroidism patients with euthyroid function after hormone replacement therapy were eligible to participate. 5) Currently using immunosuppressants or having received systemic immunosuppressive therapy (>10 mg / day prednisone or other equivalently effective hormonal agents) within 2 weeks prior to the first dose. 6) There are factors that affect oral administration (e.g., swallowing disorders, post-gastrointestinal resection, chronic diarrhea, intestinal obstruction, etc.). 7) Uncontrollable pleural, pericardial or ascites effusion requiring repeated drainage.

[0204] 8) Imaging findings (CT or MRI) show tumor invasion into large blood vessels or unclear border with large blood vessels. 9) Within 4 weeks prior to the first dose, there has been CTCAE grade 3 or higher bleeding or bloodshed, or there has been a non-healing wound, ulcer, or fracture. 10) Within 8 weeks prior to the first dose, uncontrolled symptoms of brain metastasis, spinal cord compression, carcinomatous meningitis, or brain or leptomeningeal disease as determined by CT or MRI. 11) Patients who have received radiation therapy, chemotherapy, or surgery for less than 4 weeks, oral targeted therapy for less than 5 half-lives, oral fluorouracil for less than 14 days, or mitomycin C or nitrosourea for less than 6 weeks. Patients who have had adverse events (excluding alopecia) that did not resolve to CTCAE grade 1 or lower. 12) Patients with any of the following severe and / or uncontrolled diseases: a) Inadequate blood pressure control (systolic blood pressure ≥ 150mmHg, diastolic blood pressure ≥ 90mmHg). b) Patients with unstable angina, myocardial infarction, congestive heart failure of grade 2 or higher, or arrhythmia requiring treatment (including QTc ≥ 480 ms) within 6 months prior to the first dose. c) Active or uncontrolled severe infection (CTCAE grade 2 or higher infection). d) Cirrhosis, decompensated liver disease, active or chronic hepatitis requiring antiviral treatment. *Active hepatitis (Hepatitis B: HBsAg positive and HBV DNA test value above the upper limit of normal. Hepatitis C: HCV antibody positive and HCV viral titer test value above the upper limit of normal). e) HIV positive. f) Inadequately controlled diabetes (fasting blood glucose CTCAE grade 2 or higher). g) Urine test shows urinary protein level ++ or higher and urinary protein level exceeds 1.0g in 24 hours. 13) Have received a vaccine or attenuated vaccine within 4 weeks prior to the first dose. 14) Other factors that may lead to discontinuation at the investigator's discretion, such as concurrent treatment other serious illness (including psychiatric illness) requiring further study, serious laboratory abnormalities, family or social factors affecting the subject's safety or the collection of materials and specimens.

[0205] 4.3 Test Drug Anti-PD-L1 antibody hu5G11-hIgG1 injection: 1200 mg of anti-PD-L1 antibody injection (100 mg / 10 mL) was diluted with saline to 250 mL, and the diluted drug was administered by infusion over 60 ± 5 minutes. After the infusion was completed, the tube was flushed with saline as a routine medical procedure, and the drug was administered once every 21 days. Anlotinib hydrochloride capsules (active ingredient: anlotinib dihydrochloride): 10 mg of anlotinib hydrochloride capsules were orally administered on an empty stomach 5 minutes before or after the start of anti-PD-L1 antibody infusion, for 2 weeks followed by 1 week off, for a treatment period of 21 days. Specifications: 12mg, 10mg, and 8mg.

[0206] 4.4 Evaluation Criteria The disease status will be assessed based on RECIST 1.1 / irRECIST. RECIST 1.1 evaluation criteria will be the main focus.

[0207] 4.5 Endpoints progression-free survival (PFS); Antitumor efficacy endpoints: objective response rate (ORR) = (complete response (CR) + partial response (PR)), disease control rate (DCR = CR + PR + stable disease (SD)), overall survival (OS), etc.

[0208] [Table 4]

[0209] Patient Diagnosis: Patient 01: Moderately to poorly differentiated adenocarcinoma in the upper left lung with metastases to lymph nodes and both lungs. Genotype: BRAF p.V600E. Patient 08: Left lung adenocarcinoma. Genotype: EGFR del / EGFR-T790M. Patient 011: Recurrent lung adenocarcinoma (Stage IVA) with metastases. Genotype: EGFR.

[0210] In the above examples, each treatment period took 21 days, and C2, C4, C6, C8, and C10 represent periods 2, 4, 6, 8, and 10, respectively. In the above examples, the size of the target lesion (baseline) refers to the longest diameter of the radiograph of the target lesion before the study treatment.

Claims

1. A combination pharmaceutical composition comprising an anti-PD-L1 antibody and anlotinib, The anti-PD-L1 antibody comprises the following amino acid sequences: a heavy chain CDR1 region having the amino acid sequence shown in SEQ ID NO:1, a heavy chain CDR2 region having the amino acid sequence shown in SEQ ID NO:2, a heavy chain CDR3 region having the amino acid sequence shown in SEQ ID NO:3, a light chain CDR1 region having the amino acid sequence shown in SEQ ID NO:7, a light chain CDR2 region having the amino acid sequence shown in SEQ ID NO:8, and a light chain CDR3 region having the amino acid sequence shown in SEQ ID NO:

9.

2. The combined pharmaceutical composition according to claim 1, which is used for the treatment of biliary tumors, liver cancer, triple-negative breast cancer, or lung cancer.

3. The combined pharmaceutical composition according to claim 1 or 2, comprising a pharmaceutical composition of an anti-PD-L1 antibody and a pharmaceutical composition of anlotinib.

4. The combination pharmaceutical composition according to any one of claims 1 to 3, wherein the combination pharmaceutical composition is packaged in a kit, and the kit further comprises instructions for use in combination with an anti-PD-L1 antibody and anlotinib in the treatment of biliary tumors, liver cancer, triple-negative breast cancer, and / or lung cancer.

5. The combination pharmaceutical composition according to any one of claims 1 to 4, comprising a pharmaceutical composition comprising 600 to 2400 mg of an anti-PD-L1 antibody and a pharmaceutical composition comprising anlotinib in a single dose of 6 mg, 8 mg, 10 mg, and / or 12 mg.

6. The combination pharmaceutical composition of any one of claims 1 to 5, comprising an anti-PD-L1 antibody and anlotinib in a weight ratio of (0.35-29):1, preferably (3.5-29):1, more preferably (3.5-14.5):1, and most preferably (7-14.5):

1.

7. The combination pharmaceutical composition according to any one of claims 1 to 6, wherein the combination pharmaceutical composition is a formulation suitable for administration within one treatment period, and comprises a pharmaceutical composition comprising 600 to 2400 mg of an anti-PD-L1 antibody and a pharmaceutical composition comprising 84 to 168 mg of anlotinib.

8. Use of the combined pharmaceutical composition according to any one of claims 1 to 7 in the manufacture of a medicament for treating biliary tumors, liver cancer, triple-negative breast cancer, and / or lung cancer.

9. Use of an anti-PD-L1 antibody and anlotinib in the manufacture of a medicament for treating biliary tumors, liver cancer, triple-negative breast cancer, and / or lung cancer, comprising: The anti-PD-L1 antibody comprises the following amino acid sequences: a heavy chain CDR1 region having the amino acid sequence shown in SEQ ID NO:1, a heavy chain CDR2 region having the amino acid sequence shown in SEQ ID NO:2, a heavy chain CDR3 region having the amino acid sequence shown in SEQ ID NO:3, a light chain CDR1 region having the amino acid sequence shown in SEQ ID NO:7, a light chain CDR2 region having the amino acid sequence shown in SEQ ID NO:8, and a light chain CDR3 region having the amino acid sequence shown in SEQ ID NO:

9. Use of an anti-PD-L1 antibody and anlotinib.

10. The use according to claim 8 or 9, wherein the anti-PD-L1 antibody and anlotinib are each in the form of a pharmaceutical composition and are administered simultaneously, sequentially, or at an interval.

11. The use according to any one of claims 8 to 10, wherein the anti-PD-L1 antibody is administered once a week, every two weeks, every three weeks, or every four weeks, preferably at a dose of 600 to 2400 mg.

12. 12. The use according to any one of claims 8 to 11, wherein anlotinib is administered at a dose of 6 mg, 8 mg, 10 mg, or 12 mg once daily on a regimen of 2 weeks on treatment and 1 week off.

13. A kit for treating biliary tumors, liver cancer, triple-negative breast cancer, and / or lung cancer, comprising a pharmaceutical composition of an anti-PD-L1 antibody, a pharmaceutical composition of anlotinib, and instructions for use of the anti-PD-L1 antibody and anlotinib in combination in the treatment of biliary tumors, liver cancer, triple-negative breast cancer, and / or lung cancer; The anti-PD-L1 antibody comprises the following amino acid sequences: a heavy chain CDR1 region having the amino acid sequence shown in SEQ ID NO:1, a heavy chain CDR2 region having the amino acid sequence shown in SEQ ID NO:2, a heavy chain CDR3 region having the amino acid sequence shown in SEQ ID NO:3, a light chain CDR1 region having the amino acid sequence shown in SEQ ID NO:7, a light chain CDR2 region having the amino acid sequence shown in SEQ ID NO:8, and a light chain CDR3 region having the amino acid sequence shown in SEQ ID NO:

9.

14. 14. The kit of claim 13, wherein the kit is suitable for administration within one treatment session and comprises a pharmaceutical composition comprising 600-2400 mg of an anti-PD-L1 antibody and a pharmaceutical composition comprising 84-168 mg of anlotinib.

15. The combination pharmaceutical composition according to any one of claims 1 to 7, or the kit according to claim 13 or 14, wherein the anti-PD-L1 antibody comprises the following amino acid sequences: a heavy chain variable region having the amino acid sequence shown in SEQ ID NO: 13, and a light chain variable region having the amino acid sequence shown in SEQ ID NO:

15.

16. The combination pharmaceutical composition according to any one of claims 1 to 7, or the kit according to claim 13 or 14, wherein the anti-PD-L1 antibody comprises a heavy chain amino acid sequence shown in SEQ ID NO: 17 and a light chain amino acid sequence shown in SEQ ID NO:

18.

17. The combined pharmaceutical composition according to any one of claims 1 to 7, or the kit according to claim 13 or 14, wherein the anti-PD-L1 antibody is selected from hu5G11-hIgG1 or hu5G11-hIgG4 humanized antibodies.

18. The combined pharmaceutical composition according to any one of claims 1 to 7, or the kit according to claim 13 or 14, wherein anlotinib is in the form of a free base or a pharma- ceutically acceptable salt thereof.

19. The use according to any one of claims 8 to 12, wherein the anti-PD-L1 antibody comprises the following amino acid sequences: a heavy chain variable region having the amino acid sequence shown in SEQ ID NO: 13, and a light chain variable region having the amino acid sequence shown in SEQ ID NO:

15.

20. The use according to any one of claims 8 to 12, wherein the anti-PD-L1 antibody comprises a heavy chain amino acid sequence shown in SEQ ID NO: 17 and a light chain amino acid sequence shown in SEQ ID NO:

18.

21. The use according to any one of claims 8 to 12, wherein the anti-PD-L1 antibody is selected from hu5G11-hIgG1 or hu5G11-hIgG4 humanized antibodies.

22. The use according to any one of claims 8 to 12, wherein anlotinib is in the form of a free base or in the form of a pharma- ceutically acceptable salt thereof.

23. The biliary tumor comprises gallbladder cancer, intrahepatic cholangiocarcinoma, or extrahepatic cholangiocarcinoma; or the biliary tumor comprises adenocarcinoma-type gallbladder cancer, adenocarcinoma-type intrahepatic cholangiocarcinoma, or adenocarcinoma-type extrahepatic cholangiocarcinoma; or the biliary tumor comprises surgically inoperable, late-stage, or metastatic biliary tumor; The liver cancer is hepatocellular carcinoma, or the liver cancer is selected from primary hepatocellular carcinoma, or the liver cancer is selected from the group consisting of late stage or metastatic hepatocellular carcinoma; The subject with triple-negative breast cancer has had surgery, chemotherapy, or radiation therapy; The combined pharmaceutical composition according to any one of claims 2 to 7, or the kit according to claim 13 or 14, wherein the lung cancer is selected from non-small cell lung cancer, or the lung cancer comprises lung squamous cell carcinoma or lung adenocarcinoma, or the lung cancer is EGFR or ALK wild-type non-small cell lung cancer, or the lung cancer is late stage adenocarcinoma, or the lung cancer is selected from the group consisting of late stage squamous cell non-small cell lung cancer and late stage adenocarcinoma non-small cell lung cancer.

24. The biliary tumor comprises gallbladder cancer, intrahepatic cholangiocarcinoma, or extrahepatic cholangiocarcinoma; or the biliary tumor comprises adenocarcinoma-type gallbladder cancer, adenocarcinoma-type intrahepatic cholangiocarcinoma, or adenocarcinoma-type extrahepatic cholangiocarcinoma; or the biliary tumor comprises surgically inoperable, late-stage, or metastatic biliary tumor; The liver cancer is hepatocellular carcinoma, or the liver cancer is selected from primary hepatocellular carcinoma, or the liver cancer is selected from the group consisting of late stage or metastatic hepatocellular carcinoma; The subject with triple-negative breast cancer has had surgery, chemotherapy, or radiation therapy; 13. The use of any one of claims 8 to 12, wherein the lung cancer is selected from non-small cell lung cancer, or the lung cancer comprises lung squamous cell carcinoma or lung adenocarcinoma, or the lung cancer is EGFR or ALK wild-type non-small cell lung cancer, or the lung cancer is late stage adenocarcinoma, or the lung cancer is selected from the group consisting of late stage squamous cell non-small cell lung cancer and late stage adenocarcinoma non-small cell lung cancer.

Citation Information

Patent Citations

  • Anti-b7-h1 antibodies for treating tumors

    JP2016530323A

  • Anti-PD-L1 antibody

    JP2017523786A

  • Combined Therapy for Non-Small Cell Lung Cancer with Positive EGFR Gene Mutation

    JP2018513178A